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Ail.rERATIONS OF C.ENrrnAJ.J DOPAMINE RECEPTO:R. 
SENSITIVITY IN THE SPON~-'ANEOUSLY HYPERTENSIVE RA1' 
Abstract of Thesis 
Since the time of thE: introduction of the SJ:)!Jntaneously hyper-
tensive rat (SHR) into medical researchJ sev-eral neuropharma-
cological studies have been performed on these animals whi.ch 
have been unrelated to their cardiovascular systems. A few of 
these studies have indicated possible abnormalities in the dop-
aminergi.c systems of' SHR. 'rherefore the pres~ent study was un-
dertaken to examine more closely the sensi.ti\•'ity of SI-l:H to 
stimulat:i.on of their dopamine ( DA) receptors. 
Three rat strains were utilized in this study: 1) SHR; 2) Wi-
star-Kyoto rat ( WKY); and .}) lftJistar rat ( Nli'IR)', --Three para-
meters were chosen on the basis of' their a1)pearance after 
stimulation of DA receptors in three different brain regions: 
1) stereotyped behavior via stimulation of DA receptors in the 
corpus striatum; .f.) locomotor activity via stimulation of DA 
receptors in the mesoli.mbic forebrain; and ]J hypothermia via 
stimulation of DA receptors in the hypothalamus. Apomorphine 
(APO) was chosen as the DA agonist. 
No significant difference in APO-induced stereotyped behavior 
was found to exist between the three rat strains suggesting 
that there is no alteration in the sensitivity of DA receptors 
in the corpus striatum of SHR. 
No significant difference was found to exist between the three 
rat strains with respect to either spontaneous locomotor acti-
vity or APO-induced locomotor activity suggesting that there is 
no alteration in the sensitivity of DA receptors in the meso-
limbic forebrain of SHR. 
SHR was found to be more sensitive than 11WR te the hypothermic 
effect of APO. F'rom parallel log-dose respon.se curves of the 
three rat strains, APO and a second DA agonist, L-DOPA, were 
calculatEld to be more potent in producing hy])o"thermia in SHR 
than Nt'IIR. WKY showed a hypothermic response intermediate to 
SHR and NWR. NV.JR and WKY were more susceptit:he than SHR to 
antagonism of APO-induced hypothermia by haloperidol. Chronic 
lithium treatment had no effect on APO-induced: hypothermia in 
NWR and WKY. Lithium was found to significantly attenuate APO-
induced hypothermia in SHR and to alter this. response to one 
similar to those shown by NWR and Vvl\:Y. Chrom.•ic hydralazine 
treatment in SHR had no effect on APO-inducedl. hypotht~rmia. 
Since lithium has the ability to "stabilize•~ supersensitive DA 
receptors, and APO -induced hypothermia in SHR:, it is prot)Qsed 
that DA receptors in the hypothalamus responsible for mediating 
hypothermia arc supersensitive in SHR. 
viii 
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INTRODUCTION 
A. Spontaneously Hypertensive Rat 
Development of a genetically pure strain of rat in which 
there occurs 100 perc•9nt spontaneous hypertension was re-
ported in 1963 by Okamoto and Aoki. These investigators 
isolated this strain by mating a male Wistar rat showing 
spontaneous hypertension to a female of the same strain dis-
playing a blood pressure slightly above average. This mating 
produced F1 rats. F2 rats were obtained from brother-sister 
matings of F1 rats which had been selected for their persis-
tent hypertension. Pairs of F2 rats which showed persistent 
hypertension were then selected for brother-sister matings to 
obtain FJ rats. This procedure of matings was carried on to 
the sixth generation of offspring. It was noted that the 
incidence of occurrence of spontaneous hypertension and the 
development of hypertension occurred at younger ages from 
generation to generation so that by the third generation all 
rats developed spontaneous hypertension within fifteen weeks 
of age. Since the incidence of occurrence of spontaneous 
. hypertension was 100 percent, these researchers suggested 
that this strain of Wistar rat be named "spontaneously hyper-
tensive rat (Okamoto and Aoki)" (Okamoto and Aoki, 196J). 
1 
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Being that this research was carried on at the Kyoto Univer-
sity in Japan, this particular colony of Wistar rat strain· 
from which the spontaneously hypertensive rat was isolated 
became known as Wistar-:-Kyoto. 
As an increased sympathetic tone quite often corresponds 
with hypertension, and may possibly be the cause in the spon-
taneously hypertensive rat (SHR), many investigations have 
tried to determine s~~pathetic activity in SHR. Earlier 
studies, utilizing biochemical techniques, showed a decreased 
norepinephrine (NE) turnover in cardiac tissue of SHR. Since 
NE uptake and endogenous levels were found to be the same in 
SHR as in the control rat strain, it was concluded that there 
is a decreased release of NE from heart tissue (Louis et al., 
1968; Sjoerdsma, 1972). Further studies on this organ 
indicated a reduced rate of synthesis of NE in SHR. These 
differences could not be attributed to differences in endogen-
ous levels of NE since these levels were the same in both 
strains (Louis et al., 1969, 1970; Sjoerdsma, 1972). Naka-
mura et al. (1971) confirmed the reduction in cardiac turn-
over in SHR but found that the endogenous levels were signi-
ficantly lower. Furthermore, these researchers found that the 
higher the blood .pressure the slower the NE turnover. These 
results led to the conclusion that the decrease in peripheral 
NE turnover represents a decrease in sympathetic nerve acti-
vity. This decrease 'in sympathetic activity was suggested to 
be an attempt to compensate for an increased peripheral vas-
cular resistance. 
In contrast to the biochemical evidence of a decrease in 
3 
sympathetic nerve activity in SHR, an increasing amount of 
literature suggestsan augmented sympathetic tone. Okamoto 
and coworkers (1967) found that the discharge rate of the 
left splanchnic nerve of SHR was significantly greater than 
that of control Wistar rat. Application of square pulses 
(Iriuchijima, 1973) of voltage to the peripheral cut ends of 
the left or right splanchnic nerve indicated that the num-
ber of stimulations, or frequency, required to restore ar-
terial pressure to thB level prior to nerve severance was 
significantly greater in SHR than control Wistar rat. Assum-
ing that this frequency represents the average discharge rate 
of the sympathetic vasoconstrictor fibers in the splanchnic 
nerye, it appears that SHR has a significantly greater dis-
charge rate. 
Direct measurements of sympathetic nerve activity had 
shown that there is a two- to three-fold increase in sympa-
thetic activity in SHR. This increase in sympathetic activity 
was shown to be generalized to the nerves supplying the abdomi-
nal viscera and cervical·sympathetic chain. A high correla-
tion was found between the age of SHR and their corresponding 
sympathetic nerve activity. Blockade of sympathetic ganglia 
with hexamethonium lowered the blood pressure to identical 
levels in SHR and Wistar rat (Judy et al., 1976). 
Inhibition of sympathetic nerve activity by reflex 
mechanisms indicated that the pressure-sensitive baroreceptors 
were not able to inhibit sympathetic nerve activity as effec-
tively in SHR as in normotensive Wistar rat when stimulated 
by rises in systemic arterial pressure of equal magnitude and 
4 
duration (Judy et al~, 1976; Coote and Sato, 1977). This 
reduction in effectiveness of the baroreceptors to completely . 
inhibit sympathetic nerve activity decreases as a function of 
age (Judy et al.,· 19'76). A high sympathetic activity in SHR 
has been suggested a.s the reason for the reduction in ability 
of the cardiovascular pressure receptors to inhibit ongoing 
sympathetic activity. In other words, the excitatory drive 
onto sympathetic neurons can better overcome baroreceptor 
inhibition in SHR than in Wistar rat. It was hypothesized 
that there is throughout life a continual imbalance in the 
pressure-receptor-sympathetic neuron control system which can-
not be counteracted. This imbalance was suggested to be a 
consequence of increased sympathetic·activity {Coote and Sato, 
1977). Transection experiments by Okamoto et al. (1967) indi-
cated that the increased sympathetic vasoconstrictor activity 
may originate in the ponte-bulbar portion of the brainstem. 
Since baroreceptor sinus reflex appears to be less effec-
tive in inhibiting sympathetic nerve activity in SHR, altera-
tions in baroreceptor function had been suggested as a causa-
tive factor for the hypertension. Nosaka and Wang (1972) 
found that the thr:.eshold pressure required for the carotid 
sinus to elicit hypotensive responses was significantly higher 
in SHR than in normotensive Wistar rat. Pressures required 
to stimulate maximum hypotensive responses were also signifi-
cantly higher. These results indicate that baroreceptor sen-
sitivity, at least of the carotid sinus, in SHR is shifted 
towards operating at higher pressures. No alterations in 
sensitivity of the baroreceptor response to changes in pressure 
.5 
occur with this resetting. Similar results were found for 
the aortic sinus (Sapru and Wang, 1976). Additionally, it 
was found that resetting of the baroreceptors could be pre-
vented by antihypertensive therapy of 11-week old SHR. Treat-
ment of older SHR resulted in reversal of resetting in some 
but not all animals. Histological examination of vessel 
walls revealed that reversal or prevention of aortic hyper-
trophy correlated with reversal or prevention of baroreceptor 
resetting whereas partial reversal of baroreceptor resetting 
occurred with partial reversal of hypertrophy. It was sug-
gested that high sympathetic tone results in irreversible 
hypertrophy of the tunica media of the vessel walls. This 
thickening of the aorta causes a resetting of the barorecep-
tors at a higher pressure level without altering the normal· 
sensitivity of the baroreceptor. 
Nakamura and Nakamura (1977) reported that an enhanced 
sympathetic activity in young SHR is not responsible for the 
development of hypertension. These investigators noted that 
young-pre-hypertensive SHR have elevated activities of cho-
line acetyltransferase and tyrosine hydroxylase (TH) in the 
celiac ganglia as compared to Wistar-Kyoto rat strain. Ele-
vated activities of these enzymes were not found in the super-
ior cervical ganglia, stellate ganglia or adrenal glands. 
This rise in activity of both enzymes in the celiac ganglia 
disappeared in the adult SHR. Bilateral removal of the celiac 
ganglion did not alter the development of hypertension. It 
was suggested that the faster maturation of the celiac 
ganglion in SHR is causally related to activation of the 
peripheral sympathetic nervous system. Therefore, it was 
concluded that peripheral sympathetiq activation in young 
SHR be regarded as a warning sign, but that this activation 
does not trigger the development of hypertension. 
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In contrast to Nakamura and Nakamura (1977), Vapaatalo 
et al. (1974) found that 6-hydroxydopamine (6-0HDA) given to 
newborn SHR prevented the development of hypertension. Since 
6-0HDA is known to de:stroy peripheral and central adrenergic 
nerve terminals (Mal~fors and Sachs, 1968; Thoenen and Tran-
zer, . 1968; T ranzer and Thoenen, 1968; Bloom et al. , 1969; 
Uretsky and Iversen, :l969, 1970), it was concluded that the 
sympathetic nervous system and/or adrenergic structures play 
an important part in the development of hypertension in SHR. 
It appears that interference with either of these systems 
shortly after birth can prevent the development of the bio-
chemical and/or histopathological changes·responsible for the 
development and/or maintenance of spontaneous hypertension. 
This interference could be due to either central or perip.heral 
mechanisms. It may be a central mechanism as it had pre-
viously been shown (Haeusler et al., 1972) that administration 
of 6-0HDA into the lateral brain ventricle of ?-week old SHR 
prevented the development of hypertension. Furthermore, the 
dose-response curves of vascular reactivity to NE of animals 
that developed hypertension were steeper and displayed a 
higher maximum whereas the dose-response curves of SHR treated 
with 6~0HDA were virtually identical to those of normotensive 
controls. It was proposed that there is a central trigger 
mechanism for the development of hypertension. 
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The search for a central trigger mechanism has centered 
on central catecholan1ine levels, catecholamine turnover, and 
enzyme activities. Early studies indicated a decreased NE 
synthesis in the brainstem of SHR whereas the endogenous 
levels were similar between SHR and Wistar rat (Louis et al., 
1970). Nakamura et al. (1971) found that NE levels in the 
hypothalamus and medl.Jlla-pons of 6- and 12-week old. SHR were 
the same as Wistar rat. Wistar-Kyoto rat was later found to 
also have similar NE contents in these brain regions (De 
Jong et al., 1975). No change in NE content or turnover was 
found to exist in the! brainstem of SHR in relation to changes 
in blood pressure (Nakamura et al., 1971). Yamori and co-
workers (1971) found that the NE content of the brainstem and 
hypothalamus was significantly lower in SHR than in Wistar rat. 
It was noted in 6-week old SHR that DOPA decarboxylase 
activity was 50 percent of that of Wistar rat. This reduction 
in activity was not attributed to depression secondary to the 
increased blood pressure (Yamori et al., 1970; Nagatsu et al., 
1972). Other studies also revealed a lower NE content and a 
slower rate of synthesis in the brainstem of SHR than Wistar 
rat (Sjoerdsma, 1972). However, Wistar-Kyoto rat (when this 
strain became available for study) was found to have a NE 
content similar to that of SHR (Yamabe et al., 197.3; Osumi et 
al., 1974). Similar results were found with respect to NE 
turnover when SHR were compared to Wistar-Kyoto rat. Enzyme 
studies showed that Wistar rat had significantly higher levels 
of activity of TH, DOPA decarboxylase, and dopamine-beta-
hydroxylase (DBH) than either SHR or Wistar-Kyoto rat. It 
-------~-------~~-
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appears that the variations in catecholamine levels, catechol-
amine turnover, and E~nzyme activities arise from genetic fac~ 
tors that may not be related to the pathogenesis of hyper-
tension. 
It had been suggested that these earlier studies, because 
of the gross areas investigated, failed to detect changes in 
small brain regions and that it is likely that central car-
diovascular control is mediated by individual brain areas. 
Thus Versteeg and coworkers (1976, 1978) studied smaller 
regions and found variations in SHR in regions thought to be 
involved in regulation of blood pressure. Elevated levels of 
dopamine (DA) were found in the nucleus interstitialis striae 
terminalis and frontal cortex of SHR as compared to Wistar-
Kyoto rat. No differences were found in NE and DA levels in 
the hypothalamic nuclei. Elevated level'S of epinephrine (EPI) 
were found in the hypothalamic nuclei investigated. However, 
only the nucleus paraventricularis of SHR showed a signifi-
cantly higher EPI level. Many areas of SHR brainstem had 
elevated levels of NE, including the A2-region of the nucleus 
tractus solitarii. Elevations of DA and EPI were also found 
in this region. It appears that SHR has elevated catechol-
amine levels in individual brain regions which are supposedly 
involved in the central control of arterial blood pressure. 
How these changes in brain catecholamine levels are related 
to the evolution of hypertension in SHR has yet to be deter-
mined. 
However, Nakamura and Nakamura (1978) recently reported 
observing selective activation of A2-region noradrenergic 
9 
neurons in young SHR as indicated by an increase in DBH acti-
vity. Elevated activity of this enzyme was also found in" the 
locus coeruleus and thoracic intermediolateral cell area of 
the spinal cord. This elevation of DBH activity was not 
apparent in adult SHR (Nakamura and Nakamura, 1978). Young 
SHR also had significantly elevated levels of NE and DBH, 
confirming earlier studies, which was interpreted as an in-
crease in peripheral sympathetic nerve activity (Roizen et 
al., 1975; Nagaoka and Lovenburg, 1976; Nakamura and Nakamura, 
1978). These 'investigators concluded that the selective acti~ 
vation of.noradrenergic neurons of the A2-regio:h, locus coeru-
leus, and thoracic intermediolateral cell area, in combination 
with the activation of the sympathetic nervous system, initi-
ates hypertension in young SHR (Nakamura and Nakamura, 1978). 
Several other studies have indirectly implicated a cen-
tral involvement in the hypertension of SHR. L-DOPA admin-~· 
istered to SHR significantly decreased blood pressure. Cou~ 
pling the L-DOPA with a peripheral DOPA decarboxylase inhibi~ 
tor potentiated the depressor response. Examination of brain-
stem NE levels showed that a depressor response occurred only 
when there was a concomitant rise in brainstem NE levels 
(Yamori et al., 1972). ·Judy et al. ( 1978) recently confirmed 
these results. Additionally, they found that SHR were more 
sensitive to sympathetic nerve activity inhibition by L-DOPA 
combined with a peripheral DOPA decarboxylase inhibitor. 
Greater distribution of L-DOPA to tll,e central nervous system 
\ 
of SHR was. eliminate'd as a possible explanation for these 
results as the amount of L-DOPA in the cerebral parenchyma 
-~ ----~--~-----
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was equivalent in both rat strains (Judy et al., 1978). It 
appears· that there mia.y be a highly significant inverse rela-
tionship between bra:lnstem NE levels and blood·pressure 
( Yamori et al. , 1972). 
Like the brainstem, the hypothalamus has also been impli-
cated in the development of hypertension in SHR. Yamori and 
Okamoto (1969) discovered that when the neural connection be-
tween the posterio~ hypothalamus and mesencephalon was separ-
ated, a significantly greater fall in blood pressure was eli-
cited in SHR as compared to Wistar rat. Other separations in 
the hypothalamus or l)etween the hypothalamus and other brain 
structures were ineffective in producing depressor responses. 
These results provide evidence of hypothalamic tonic influence 
on blood pressure and its participation in pathogenesis of 
hypertension in SHR. 
Various studies have shown that the posterior hypothala-
mus mediates pressor responses (Karpus and Kreidl, 1918, 1927) 
while the anterior hypothalamus mediates depressor responses 
(Folkow et al., 1959, 1964; Phillippu and Schartner, 1976). 
---
EPI and NE may be the neurotransmitters involved in the de-
pressor response (Struyker Boudier and Bekers, 1975; Struyker 
Boudier, 1975). Intrahypothalamic increases in cyclic-AMP 
(cAMP) have been shown to result in press.or responses. Con-
versely, decreases in cAMP result in depressor responses 
(Walland, 1975). Weak electrical stimulations of the poster-
ior hypothalamus, which were ineffective in Wistar rats, were 
found to elicit measurable responses in SHR. Currents above 
threshold always elicited greater pressor responses in SHR. 
------ ------------
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Hypersensitivity of the posterior hypothalamic pressor areas 
_ of SHR was considerEid as an explanation for these results. 
However, possible hypersensitivity of other sites in the 
efferent neural pathway could not be excluded (Bunag et al., 
1975). Hypothalamic concentrations of cAMP has recently been 
shown to be lower in SHR than in Wistar-Kyoto rat whereas 
cortical levels of c:AMP did not differ. It was suggested . 
that reduced levels of hypothalamic cAMP may be related to 
the elevated blood pressure of SHR. In: any case, these re-
sults indicate a possible alteration of the adenylate cyclase-
cAMP-phosphodiesterase system in hypothalamic structures of 
SHR (Schmid et al., 1978). 
Because of the possible variations of catecholamine 
levels within certain brain regions of SHR, several behavioral 
studies have been performed on this particular rat strain. 
Open field tests had indicated that SHR were at a lower emo-
tional state than Wistar rat (Shimamoto and Nagaoka, 1972; 
Pappas et al., 1974). A greater excitement of the cortex of 
SHR had been postulated from their apparently greater spon-
taneous activity (Shimamoto and Nagaoka, 1972; Pappas et al., 
1974; Myers et al., 1977). Greater cortical excitement may 
be related to the finding that SHR were more sensitive to 
electroshock seizures. This increased sensitivity was cor-
related with a slower turnover of NE in the brainstem and 
cortex and of DA in the striatum (Goldberg et al., 1975). 
Behavioral responses induced by methamphetamine, apomor-
phine and L-DOPA have been assessed by scoring. Methamphet-
amine caused greater behavioral excitement in SHR as indicated 
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by a!). increase in pE~ak effect and duration of action. Sub-
cutaneous administration of apomorphine resulted in similar 
stereotyped gnawing behavior in both SHR and Wistar rat. 
L-DOPA also resulted in similar behavioral responses. It was 
concluded from these drug-induced behavioral changes that SHR 
are more susceptible to release of DA from corpus striatum 
( Shimamoto and Naga_oka, 1972). 
Sidman avoidance response rates showed that the average 
avoidance response in SHR increased after the fifth test and 
remained significantly higher than that shown by Wistar rat 
(Takaori et al., 19'?2). Rosecrans and Adams (1976) also 
observed higher avoidance rates which they interpreted as be-
ing in,dicative of a lower emotional· state. Treatment with 
para-chlorophenylalanine (J2.-CPA) resulted in an increase in 
avoidance in both strains, but the increase in SHR was not 
significant due to the higher initial level. L-5-hydroxy-
tryptophan (5-HTP) n~rkedly lowered the frequency ot avoidance 
responses in SHR whereas only a high dose lowered the fre-
quency in Wistar rat. Treatment with alpha-methyltyrosine 
had no effect on the avoidance rates. L-DOPA produced a 
slight increase in avoidance response in Wistar rat, whereas 
the same dose_ caused a marked decrease in frequency in SHR. 
Since 12.-CPA depleted brain serotonin and 5-HTP increased 
brain serotonin, these results indicate that there may be an 
abnormality in serotonin metabolism in SHR. Additionally, the 
response to L-DOPA may indicate an alteration in SHR brain 
catecholamine metabolism as there were observable increases 
in central catecholamine levels (Takaori et al., 1972). 
1J 
In keeping with the possibility of abnormal serotonin 
metabolism in SHR, Ro·secrans and Adams ( 1978) attempted to 
correlate changes in serotonin metabolism to changes in be-
havior. These investigators found enhanced serotonin turn-
over in cerebral cortex, diencephalon, and brainstem, with 
significantly inc~eased turnover occurring in the limbic 
forebrain. SHR were found to be less active than the Wistar 
rat upon initial testing of spontaneous motor activity, an 
observation incon~istent with previous studies. When SHR 
were subjected to repeated testing situations they were 
found not to habi tuat,e as readily as Wistar rat, as evidenced 
by an eventual higher spontaneous activity than Wistar rat. 
Similar results were obtained with respect to rearing. It 
was concluded that habituation is an active process which is 
retarded in SHR because of hyperfunctional serotonergic 
systems· • 
. Body temperature studies by Tanaka and others ( 1972) 
showed that the body temperature response of SHR to L-DOPA 
differed from that displayed by Wistar-Kyoto rat. These 
investigators found that L-DOPA alone was able to cause hypo-
thermia in SHR. L-DOPA administered alone to Wistar-Kyoto 
rat resulted in a hyperthermic response. Only when L-DOPA 
was coupled with a peripheral DOPA decarboxylase inhibitor 
pretreatment was a hypothermic response in Wistar-Kyoto rat 
observed. Since L-DOPA-induced hyperthermia is mediated peri-
pherally and hypothermia centrally,, these researchers con-
cluded.that this difference in temperature response was due 
to the presence of a more permeable blood-brain-barrier in 
-------- ~-------~ 
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SHR. 
B. Apomorphine-Induced Stereotypic Behavior in the Rat 
Administration of apomorphine to rats results in its 
accumulation within minutes in all brain regions (Butter-
worth and Barbeau, 1974). As a consequence of its presence, 
a behavioral syndrome is elicited which follows a time course 
that parallels this accumulation (Butterworth and Barbeau, 
1974). This behavioral syndrome is known as "stereotyped 
behavior", and consists largely of purposeless, repetitive, 
compulsive movements. These movements begin as discontinuous 
sniffing which progresses to continuous sniffing concomitant 
with repetitive head and forelimb movements. Increased loco-
motor activity then occurs in the presence of this continuous 
sniffing giving the impression of exploratory activity. This 
behavior is eventually replaced by continuous gnawing, biting, 
or licking as the rat restricts its motor activity, if any, 
to a single area. The purposeless, repetitive, compulsive 
nature of this activity justifies its "stereotyped" label 
(DiChiara and Gessa, 1978). 
The importance of the corpus striatum in the mediation 
of the apomorphine-induced gnawing behavior was demonstrated 
very early (Harnack, 1874; Amsler, 192J). Ernst and Smelik 
(1966) narrowed down the location by implanting microquanti-
ties of DOPA or apomorphine into various regions of the brain. 
The gnaw-syndrome was elicited only when these chemicals were 
administered to the dorsal part of the caudate nucleus and 
globus pallidum. No change in behavior was observed when 
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either of these drugs was implanted into the ventral caudate 
nucleus, nucleus lateralis septi, subthalamic structures, or 
the substantia nigra. It was concluded that the specific area 
of the caudate nucleus that is involved in this syndrome is 
I 
the neostriatum. It was suggested that accumulation of DA in 
this structure, as shown by Bertler and Rosengren (1959), is 
responsible for the gnawing behavior and that apomorphine, be-
cause of its structural similarity to DA, is able to stimulate 
DA receptors thus mimicking the effects of DA (Ernst and Sme-
lik, 1966). Dose-dependent increases in stereotyped behavior 
were observed when apomorphine was injected into the caudate 
nucleus while bilateral electrocoagulation of this region in-
hibited the response to intraperitoneally-administered apomor-
phine (Nagy and Decsi, 1977). The course of study on the pu-
tative dopaminergic agonistic activity of apomorphine has tak-
en two routes: 1) those which have employed biochemical tech-
niques, and ~) those which have utilized whole animals. 
Several studies have determined the amount of DA deple-
tion after inhibition of TH with alpha-methyltyrosine. These 
studies have consistently shown that apomorphine causes a 
retardation of DA depletion (Anden et al., 1967; Butcher and 
Anden, 1969). Unilateral transection of the nigrostriatal 
pathway interrupts the concentration of DA at striatal re-
ceptor sites. Treatment with the DA receptor blocker, halo-
peridol, after DOPA decarboxylase inhibitor pretreatment, was 
found to have no effect on the lesioned side while the intact 
side showed an increase in DOPA concentration (Kehr et al., 
1972). Apomorphine treatment resulted in a bilateral decrease 
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in DOPA concentrations which could be antagonized by halo-
peridol. Measurement of DA levels indicated that apomorphine 
reduced DA to similar levels on the intact side (Kehr et al.; 
1972). Further experiments demonstrated that apomorphine was 
able to significantly decrease the extraneuronal metabolite 
of DA, homovanillic acid (Roos, 1969). From these results it 
was concluded that apomprphine is able to reduce the activity 
of DA neurons via a negative-feedback mechanism due to stimu-
lation of DA receptors (Anden et al., 1967; Butcher and Anden, 
1969), and that this feedback mechanism controls the rate of 
tyrosine hydroxylation (Kehr et al., .19?2). 
Apomorphine was also demonstrated to decrease TH activity 
in synaptosomes while haloperidol had little or no effect. 
Haloperidol did partially attenuate the inhibitory action of 
apomorphine on TH. It was postulated that haloperidol may be 
able to block only one of two actions that apomorphine may 
have on TH activity (Christiansen and Squires, 1974). Besides 
apparently reducing TH activity by a receptor-mediated feed-
back mechanism as a result of direct DA receptor stimulation, 
apomorphine may also directly inhibit this enzyme. Goldstein 
and coworkers (1970) found that apomorphine could inhibit TH 
as well as inhibit the synthesis of DA from tyrosine in stri-
atal slices. Haloperidol added to the striatal slices did 
not affect the inhibitory action of apomorphine. Thus it may 
be that apomorphine, besides decreasing TH activity indirectly 
via a feedback mechanism, may also be able to directly inhibit 
TH activity. This was considered to be in agreement with its 
cathechol stucture (Golstein et al., 1970). 
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Structural examination of the apomorphine molecule also 
sug~ests that it is capable of possessing dopaminergic acti-
vity. By studying the. gnaw-syndrome in rats, Ernst ( 1964, 
1967) determined a phenylethylamine configuration with a hy-
droxy-group at the para-position, or at the para- and meta-
positions of the phenol-ring is necessary for the gnaw-syn-
drome. Other studies implicated the requirement of the dihy-
droxytetrahydroaminonaphthalene moiety for the induction of 
the gnaw-syndrome (Pinder et al., 1971, 1972), which is sup-
ported by molecular orbital calculations using the extended 
HUckel theory (Rekker et al., 1972). These data indicate that 
the active structures of dopamine and apomorphine are extreme-
ly similar. 
The specificity of apomorphine for inducing changes in 
DA neuron activity was shown by Anden and others (1967). Apo-
morphine was found to be ineffective on the flexor reflex in 
. spinalized rats in contrast to noradrenergic receptor stimu-
lants. They also found that apomorphine did not influence 
the disappearance of NE from the brain or spinal cord after 
TH inhibition with alpha-methyltyrosine. Furthermore, halo-
peridol, a rather specific DA receptor blocker (Van Rossum, 
1966), blocked the effects of apomorphine (Anden et al., 1967). 
Demonstration of direct DA receptor stimulation action 
by apomorphine has also been shown in animals pretreated with 
enzyme inhibitors or catecholamine depletors. Pretreatment 
of rats with alpha-methyltyrosine or alpha-methyldopa did 
not block the stereotypic action of apomorphine (Ernst, 1967). 
Costall and Naylor (197Ja) found that reserpine, as well as 
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alpha-methyltyrosine, enhanced apomorphine-induced stereo-
typed behavior. 6-0HDA administered intraventricularly to 
rats was found to enhance some of the stereotypic effects 
(Schoenfeld and Uretsky, 1972) while a separate study showed 
potentiation of all stereotypic effects (Price and Fibiger, 
1974). Although finding no significant difference in the log-
dose response curves between rats treated intraventricularly 
with 6-0HDA and untreated rats, Jalfre and Haefely (1971) de-
monstrated that haloperidol completely blocked the gnawing re-
sponse to apomorphine. 6-0HDA-induced lesions of the caudate 
nucleus also resulted in enhanced apomorphine-induced stereo-
typed behavior (Kelly et al., 1975; Iversen et al., 1975). 
An earlier study indicated that bilateral lesions of the sub-
stantia nigra with 6-0HDA resulted in furious compulsive gnaw-
ing which was far more violent than after the same dose of apo-
morphine administered to a normal rat (Uhgerstedt, 1971). 
These results provide further evidence that apomorphine is 
capable of directly stimulating DA receptors. 
Besides observing an enhancement of stereotypy in intra-
ventricularly 6-0HDA-treated rats, Schoenfeld and Uretsky 
(1972) noted that this treatment abolished gnawing suggesting 
that intact dopaminergic neurons are necessary for full 
expression of apomorphine-induced stereotypy. Oxyperitine and 
Ro 04-1284 were also found to reduce or abolish the stereo-
typy (Costall and Naylor, 197Ja). Electrolytic bilateral 
ablation of the substantia nigra or lesions of the ascending 
dopaminergic fibers of the nigrostriatal pathway abolish or 
reduce apomorphine-induced stereotypy (Costall et al., 1972; 
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Costall and Naylor, 197Jb). From these findings it appears 
that the action of apomorphine depends to a great extent on 
intact dopaminergic neurons. 
Studies which have utilized electrolytic lesions have 
been criticized on the basis that this technique not only 
disrupts dopaminergic pathways, but also interrupts the func-
tion of other pathways. Unilateral intranigral injection of 
kainic acid produces rotation of the treated animal to the 
side away from the lesion, or contralateral turning. Similar-
ly, unilateral electrolytic lesions of the substantia nigra 
also result in contralateral turning. In contrast, uni-
lateral lesion of the nigrostriatal dopaminergic pathway by 
intranigral injection of 6-0HDA, which is just as effective 
in destroying dopaminergic neurons as electrolytic lesions, 
results in turning towards the side of the lesion, or ipsi-
lateral turning. Since it was shown that kainic acid pro-
duced contralateral turning independently of dopaminergic 
nigrostriatal function, it was postulated that non-dopaminer-
gic neurons exist in the substantia nigra which control 
turning behavior in a manner opposite to that of the nigro-
striatal dopaminergic neurons. These results were suggested 
to provide an explanation for some turning responses obtained 
from electrolytic lesions of the substantia nigra or nigro-
striatal pathway which are not readily explained by an action 
on the nigrostriatal DA system (DiChiara et al., 1977; Olianas 
et al., 1978). Some of these other non-dopaminergic pathways, 
which could easily be disrupted by electrolytic lesions, may 
be necessary for complete expression of apomorphine-induced 
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stereotyped behavior (DiChiara and Gessa, 1978). 
In addition to these postulated pathways, other neuro-
transmitters and brain structures have been implicated in the 
mediation of the stereotypic effects of apomorphine. Thus it 
was found that electrocoagulation of the noradrenergically-
innervated nucleus amygdaloideus lateralis abolished the 
gnawing, biting, and licking behavior induced by apomorphine 
while intensifying the sniffing behavior and the repetitive 
movements. It was suggested that the nucleus amygdaloideus 
lateralis, and therefore noradrenergic neurons, are involved, 
either directly or indirectly, in the mediation of the gnaw-
ing, biting, and licking components of apomorphine-induced 
stereotyped behavior (Costall and Naylor, 1972). These obser-
vations were similar to those of Schoenfeld and Uretsky (1972). 
Intraventricular administration of 6-0HDA may have depleted 
the noradrenergic stores of the nucleus amygdaloideus lateralis 
thereby abolishing the gnawing, biting, and licking components 
of apomorphine-induced stereotypy while allowing the enhance-
ment of the sniffing and repetitive movements. 
It is becoming apparent that some of the dopaminergically-
innervated structures of the mesolimbic forebrain are also 
important in the mediation of apomorphine stereotypy. It was 
found that bilateral destruction of the tuberculum olfactorium 
markedly reduced apomorphine-induced stereotyped behavior in 
the rat (McKenzie, 1972; Costall et al., 1973, 1975). Destruc-
tion of the nucleus accumbens was less effective than tuber-
culum olfactorium lesions in reducing the effects of apomor-
phine while both of these regions were found to be essential 
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for the development of sniffing and repetitive head movements 
(Costall and Naylor, 1973). Similarly, lesions of the ascend-
ing dopaminergic fibers to the mesolimbic forebrain reduced 
apomorphine-induced stereotyped behavior. In contrast to 
reductions, Kelly and coworkers (1975) found that 6-0HDA 
lesions of the nucleus accumbens enhanced the sniffing be-
havior upon subsequent treatment with apomorphine. These 
results indicate that the mesolimbic forebrain is important 
in mediating the sniffing and repetitive movements induced 
by apomorphine. 
A detailed examination (Costall et al., 1975) of the 
stereotypic effects induced by apomorphine revealed that these 
effects can be differentiated into two dose-dependent components. 
Low doses of apomorphine result in the appearance of the low-
intensity component which consists of sniffing, and repetitive 
head and limb movements. Higher doses of apomorphine result in 
the high-intensity component consisting of gnawing, biting, or 
licking. By various central lesions and subsequent administra-
tion of apomorphine, these two components were found to be 
mediated by different brain regions. Bilateral lesions of 
the caudate putamen (neostriatum) failed to have any effect 
on apomorphine-induced stereotypy (Divac, 1972; McKenzie, 
1972; Costall et al., 1973, 1975). Intracaudate administra-
tion of apomorphine resulted in the development of periodic 
biting without sniffing and repetitive head and limb move-
ments. Lesions of the substantia nigra abolished the biting 
response without affecting the low-intensity component. 
Lesions of the nucleus accumbens abolished the sniffing 
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response to apomorphine while enhancing the intensity of the 
biting component. Injection of apomorphine into this nucleus 
resulted in sniffing behavior that was dose-dependent. Bit-
ing was also observed but did not appear to be dose-dependent. 
Lesions of the tuberculum olfactorium also abolished the low-
intensity component. However, the biting component was also 
reduced. Administration of apomorphine into the tuberculum 
olfactorium resulted in the development of both high- and 
low-intensity components of stereotypy. As with the nucleus 
accumbens, the intensity of sniffing appeared to be dose-
dependent whereas the biting response remained periodic at 
all doses. It appears that the high-intensity component of 
apomorphine-induced stereotyped behavior is mediated largely 
by the extrapyramidal systems, while the low-intensity compo-
nent is mediated by the mesolimbic system (Costall et al., 
1975). 
Recently, Ljungberg and Ungerstedt (1977a) reported 
observing two independent behavioral patterns elicited by 
subcutaneous (s.c.) injections of apomorphine. These two 
behavioral patterns seem to follow the loW- and high-intensity 
components described by Costall et al. (1975). Low-intensity 
behavior was observed when apomorphine (as the base) was 
dissolved by heating and injected s.c. into the neck, or 
when it was dissolved by heating together with a high concen-
tration of ascorbic acid and injected s.c. into the flank or 
neck. High-intensity behavior resulted when apomorphine, 
dissolved by heating, was injected s.c. into the flank. Addi-
tionally, it was found that these results were not merely due 
--~---········----·---
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to differences in dose as the low-intensity responses could 
not be obtained by lowering the dose of the high-intensity 
treatment, and the high-intensity responses could not be ob-
tained by increasing the dose of the low-intensity treatment. 
Failure of being able to change the intensity of the response 
by changing the dose of apomorphine suggests that the sniff-
ing and repetitive head and limb movements are not of a lower 
intensity than compulsive gnawing as previously suggested. 
Additional studies showed that apomorphine-induced gnaw-
ing is greatly affected by such factors as test environment 
and experimental design. Locomotion, which usually occurs 
simultaneously with the apomorphine-induced sniffing behavior, 
was shown to be essentially independent of these factors. It 
was found that restricting an animaL'.s ability to locomote by 
restricting its area in which to move did not increase its 
gnawing behavior. However, it was shown that pretreatment of 
these rats with a dose of clozapine that is able to antago-
nize apomorphine-induced locomotion without affecting gnaw-
ing behavior could change the locomotor behavior to gnawing 
behavior. It was suggested that these results indicate that 
apomorphine-induced locomotion is more compulsive than the 
so-called "compulsive gnawing" (Ljungberg and Ungerstedt, 
1978). 
c. Dopaminergic Involvement in Control of Locomotor Activity 
in Rat 
A role for DA has been suggested in the control of loco~ 
motor activity in the rat. Marked increases in both locomotor 
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activity and brain levels occurred when rats were peripherally 
administered L-DOPA coupled with a DOPA decarboxylase inhibitor 
pretreatment. Although NE levels remained unchanged, increases 
in motility only occurred in the presence of sufficient NE 
(Ahlenius and Engel, 1971; Maj et al., 1971; Friedman and Ger-
shon, 1972). These results agreed with an earlier study (Ever-
ett and Weigand, 1962) which indicated that both DA and NE were 
important in L-DOPA-induced locomotor activity. L-DOPA coupled 
with a monoamine oxidase inhibitor (MAO-I) pretreatment re-
sulted in an increase in brain levels of both DA and NE, as 
well as stimulating locomotor activity (Green and Kelly, 1976; 
Heal et al., 1976). Rats pretreated with a DBH inhibitor 
known to reduce brain NE concentration had no effect on the 
N~O-I/L-DOPA-induced locomotor activity (Green and Kelly, 1976). 
Dopaminergic receptor blockers were found to antagonize the 
increase in activity (Heal et al., 1976). Thus it appears 
that DA receptor stimulation is necessary for locomotion 
while the role of NE remains equivocal. 
Intraventricular injection of DA was found to result in 
an increase in locomotor activity that was dose-dependent. 
Examination of brain levels of DA and NE indicated that a low 
dose of DA did not result in significant changes whereas a 
high dose resulted in significantly higher levels of DA which 
gradually decreased as NE levels increased (Malec and Klein-
rok, 1972). Costal~ and coworkers (1975, 1976a) observed 
dose-dependent hyperactivity after bilateral injection of DA 
into the nucleus accumbens. Nialamide (Pijnenburg and Van 
Rossum, 1973; Costall and Naylor, 1975; Costall et al., 1976a) 
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or reserpine/nialamide pretreatments (Anden and Jackson, 
1975) were ~ound to strongly enhance locomotor activity. 
Bilateral administration of NE to this nucleus after niala-
mide pretreatment only slightly enhanced locomotor activity 
(Pijnenburg and VanRossum, 197.3). Bilateral injection of 
DA,into the tuberculum olfactorium resulted in periodic in-
creases in locomotor activity (Costall and Naylor, 1975) 
whereas only a slight to moderate increase occurred after 
administration to the caudate nucleus (Pijnenburg and Van 
Rossum, 197.3). Although it appears that dopaminergic recep-
tors of the nucleus accumbens are involved in the control of 
locomotor activity, the possible involvement of NE could not 
be conclusively excluded by these studies. 
Later studies performed by Costall and Naylor (1976a) 
showed that the dose-dependent increases in locomotor acti-
vity produced by bilaterally-applied DA to the nucleus accum-
bens of nialamide pretreated rats could be antagonized by 
intraperitoneal administration of the so-called typical DA 
receptor blockers (haloperidol, fluphenazine, pimozide, clo-
thiapine) and atypical DA receptor blockers (clozapine, sul-
piride, thioridazine). Systemic administration of pimozide to 
reserpine/nialamide pretreated animals effectively antagonized 
the locomotor activity produced by DA injected bilaterally 
into the nucleus accumbens (Jackson et al., 1975). The alpha-
adrenergic antagonist, phenoxybenzamine, and the beta-adrener-
gic antagonist, propranolol, were both ineffective in block-
ing the hyperactivity (Jackson et al., 1975). These studies 
provide further evidence that dopaminergic receptor mechanisms, 
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while not necessarily noradrenergic receptor mechanisms, are 
involved in the control of locomotor activity. 
Several other studies have attempted to determine the 
importance of DA and NE in the control of locomotor activity. 
Pijnenburg and coworkers (1975a) used amphetamine to differen-
tiate the contribution of these two amines to the control of 
locomotor activity. Haloperidol administered bilaterally 
into the nucleus accumbens blocked amphetamine-induced hyper-
activity while administration of the alpha-adrenergic antago-
nist, phentolamine, or propranolol, did not significantly 
inhibit locomotor stimulation. Bilateral administration of 
haloperidol into the caudate nucleus did not inhibit amphet-
amine-induced locomotor activity. Haloperidol antagonized 
the locomotor stimulation by both DA and NE injected into 
the nucleus accumbens of nialamide pretreated rats (Pijnen-
burg et al., 1975b). Phentolamine, on the other hand, poten-
tiated the hyperactivity produced by both of these amines, 
suggesting that the stimulation of locomotor activity induced 
by NE is the indirect result of dopaminergic mechanisms 
(Pijnenburg et al., 1975b). NE and the alpha-adrenergic ago-
nists, clonidine and phenylephrine, injected into the nucleus 
accumbens of non-pretreated animals produced depression 
rather than stimulation while DA resulted in a significant 
increase in locomotor activity which could be antagonized by 
haloperidol (Pijnenburg et al., 1976). These results agree 
with the earlier studies which implicate dopaminergic recep-
tors of the nucleus accumbens in the control of locomotor 
activity. Although the results on NE inv6lvement remain 
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equivocal, this neurotransmitter may be indirectly involved 
via dopaminergic systems in the control .of locomotor acti-
vity. 
Apomorphine unexpectedly produced both stimulant and 
depressant effects when applied bilaterally into the nucleus 
accumbens, but produced locomotor stimulation when applied 
bilaterally into the tuberculum olfactorium (Pijnenburg et 
al., 1976). In contrast, Jackson and coworkers ( 1975J found 
apomorphine induced locomotor activity similar to that pro-
duced by DA applied bilaterally into the nucleus accumbens. 
Systemic administration of apomorphine was shown by Maj 
et al. (1972) to stimulate an increase in locomotor activity. 
Haloperidol and spiroperidol blocked the increase induced by 
lower doses of apomorphine while higher doses were able to 
overcome the blockade. Phenoxybenzamine antagonized the 
higher doses suggesting the involvement of NE in apomorphine-
induced hyperactivity. Furthermore, alpha-methyltyrosine, 
dimethyldithiocarbamate, and disulfiram partly inhibited the 
locomotor effect of apomorphine. It was concluded that both 
DA and NE are involved in the control of motility in rats, 
and that apomorphine induces hyperactivity in rats by direct 
stimulation of DA receptors (Maj et al., 1972). In a follow-
ing report, Maj and coworkers (197J) found that alpha-methyl-
tyrosine did not significantly affect the locomotor response, 
although the motility induced by apomorphine was reduced by 
this treatment. 
Systemic administration of apomorphine to rats with 
bilateral 6-0HDA lesions of the nucleus accumbens resulted in 
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an enhanced locomotor response which could be blocked by pimo-
zide (Iversen et al., 1975). 
In contradiction to their results obtained with DA, 
Costall and coworkers (1975) found that bilateral injections 
of apomorphine directly into the nucleus accumbens resulted 
in activity that was indistinguishable from that exhibited 
by animals receiving solvent injections. In later studies, 
Costall and Naylor (1976b) discovered that systemically-ad-
ministered apomorphine in substereotypic doses was able to 
antagonize, in a dose-dependent manner, the hyperactivity 
induced by DA administered directly into the nucleus accum-
bens. Furthermore, apomorphine administered directly into 
the nucleus accumbens was able to antagonize the locomotor 
stimulant effect of directly applied DA. It was suggested 
that these results may indicate that while apomorphine has 
affinity for the DA receptors in the nucleus accumbens, it 
may lack intrinsic activity. These authors also speculated 
on the possible activity that apomorphine may have on sero-
tonin mechanisms in the nucleus accumbens (Costall and Naylor, 
1976b)~ 
Earlier studies had shown that lesions of the midbrain 
raphe nucleus resulted in marked decreases in the levels of 
serotonin and its metabolite, 5-hydroxyindoleacetic acid 
(5-HIAA), in the forebrain. A concomitant increase in loco-
motor activity was observed suggesting that serotonin may play 
an inhibitory role in the control of locomotor activity (Kos-
towski et al., 1968). Electrolytic lesions of the medial ra-
phe nucleus resulted in an enhanced locomotor response to apo-
-----------
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morphine (Grabowska, 1974) while pretreatment of animals 
with the serotoninolytics, methysergide and brom-lysergic 
acid diethylamide, also enhanced apomorphine-induced hyper-
activity (Grabowska and Michaluk, 1974). It was hypothesized 
that serotonin plays an inhibitory role in apomorphine-
induced locomotor stimulation in rats. Since it had also 
been observed that the decline of apomorphine-induced hyper-
activity was inversely related to the elevation of 5-HIAA con-
centration, it was suggested that apomorphine activates cen-
tral serotonin neurons and thereby attenuates its own stimu-
latory effect on locomotor activity (Grabowska et al., 197.3a). 
Indirect support for this hypothesis was provided by Costall 
et al. (1976b) when they showed that serotonin injected into 
the nucleus accumbens resulted in dose-dependent reductions 
in the hyperactivity induced by prior injections of DA. Lar-
ger doses completely abolished the DA effect. When forebrain 
concentrations of serotonin were reduced by lesions of the 
medial raphe nucleus, it was found that the hyperactivity 
response to DA was markedly enhanced. These results were 
suggested to indicate that the facilitatory effect of DA on 
locomotion may be modulated by an inhibitory influence from 
serotonergic mechanisms (Costall et al., 1976b). It was also 
noted that the antagonism of the DA-induced locomotor activity 
by serotonin after injections of these putative neurotrans-
mitters into the nucleus accumbens was similar to that pro-
duced by apomorphine administered in the same manner (Costall 
and Naylor, 1976b). 
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D.·· Apomorphine- And L-DOPA-Induced Hypothermia in Rat 
Apomorphine has been consistently reported to cause a 
decrease in the core body temperature of the rat (Kruk and 
Brittain, 1972; Kruk, 1972; Yehuda and Wurtman, 1972; Han-
sen and Whisaw, 1973; Grabowska et al., 1973b; Grabowska, 
1974; Scheel-Kruger and Hasselager, 1974; Chiel et al., 
1974; Przewlocki, 1976, 1977; Ary et al., 1977; Cox and Lee, 
1977a, 1977b). Various injection methods have been used in 
these numerous studies. Kruk and Brittain (1972) found that 
intraventricular injection of apomorphine resulted in a fall 
in core temperature along with a rise in skin temperature. 
Kruk (1972) reported a dose-dependent decrease in core body 
temperature and an increase in skin temperature after intra-
ventricular administration of apomorphine. Pretreatment 
with pimozide antagonized the activity of apomorphine. 
Similarly, several other studies have shown that pimozide 
and spiroperidol can block the hypothermic action of sys-
temically-administered apomorphine (Yehuda and Wurtman, 1972; 
Grabowska et al., 1973b). It appears that apomorphine 
mediates hypothermic responses through activation of DA re-
ceptors. 
Development of tolerance to the hypothermic effects .of 
apomorphine has been shown to occur with repeated administra-
tion. Chiel and coworkers (1974) showed that weekly injec-
tions of apomorphine resulted in a gradual decline in the 
hypothermic response. It was suggested that the development 
of tolerance was due at least in part to alterations in the 
sensitivity of DA receptors. 
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The site of action of apomorphine has been demonstrated 
by Cox and Lee (1977a, 1977b) to reside within the preoptic-
anterior hypothalamus. Administration of apomorphine into 
the preoptic-anterior hypothalamus and the lateral ventricle 
resulted in hypothermic responses. The response elicited from 
intrahypothalamic administration was of greater magnitude and 
took significantly less time to develop. A separate study 
(Ary et al., 1977) reported similar results. In addition it 
was found that hypothermia induced by systemic injections of 
apomorphine could be antagonized by pretreatment with pimozide 
injected into the rostral hypothalamus. Intraventricular 
administration of pimozide did not block the hypothermic re-
sponse to systemically-administered apomorphine. Tolerance 
was discovered to·occur to repeated injections of apomorphine 
given both systemically and intrahypothalamically. Repeated 
injections of apomorphine into the lateral ventricle did not 
result in the development of tolerance. It was suggested 
that apomorphine can induce hypothermia via two different 
types of DA receptors at two different sites: 1) in the ros-
tral hypothalamus where the receptors develop tolerance and 
where the temperature is due to a downward shift in the set 
point as determined by behavioral thermoregulation studies; 
and g) in areas surrounding the lateral ventricle where recep-
tors do not develop tolerance (Ary et al., 1977). The possi-
bility of a relay from the lateral ventricular sites to the 
hypothalamus was also suggested. 
Since serotonin has been shown to be involved in the 
control of locomotor activity, the possible involvement of 
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this putative neurotransmitter in apomorphine-induced hypo-
thermia has also been investigated. Grabowska (1974) found 
that lesions of the medial raphe nucleus attenuated the hypo-
thermia caused by apomorphine. Contradictory results were 
reported by Przewlocki (1977) who found that electrolytical 
and chemical lesions of both the dorsal and medial raphe 
nuclei prevented apomorphine-induced hypothermia. Lesions 
of the medial raphe nucleus by both methods did not affect 
the fall in body temperature whereas lesions of the dorsal 
raphe nucleus attenuated the hypothermia. Additionally, 
bilateral electrolytic lesions of the caudate nucleus, sub-
stantia nigra, or nucleus accumbens did not affect or poten-
tiated the hypothermic response. It was concluded that meso-
limbic dopaminergic neurons were not involved in the hypo-
thermia elicited by apomorphine, whereas the neurons of the 
dorsal raphe nucleus may be involved in this action of apo-
morphine (Przewlocki, 1977). On the basis of these results, 
it has been suggested that part of the hypothermic action of 
apomorphine may possibly be the result of indirect activation 
of serotonergic neurons which originate in the midbrain (Gra-
bowska, 1974; Przewlocki, 1976). 
The results of locomotor activity studies have suggested 
that L-DOPA-induced increases in locomotion in the rat are 
related to the conversion of L-DOPA to DA with subsequent 
activation of DA receptors. L-DOPA has also been shown to 
decrease body temperature which could be assumed to also be 
due to the formation of DA and stimulation of DA receptors in 
the preoptic-anterior hypothalamus. However, Reichenburg and 
--------
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Vetulani (1973) reported that hypothermia induced by intra-
ventricular injection of L-DOPA was unaffected by spiroperi-
dol. Maj and Pawlowski (1973) confirmed these results by 
showing that L-DOPA administered with a peripheral DOPA de-
carboxylase inhibitor also elicited a hypothermic response 
which was unaffected by spiroperidol or pimozide. Additionally, 
the L-DOPA treatment caused a decrease in brain serotonin 
levels while increasing .5-HIAA levels. Since the serotonin 
depletor £-CPA attenuated both the fall in body temperature 
and the changes in brain serotonin and .5-HIAA levels, it 
was suggested that the release of serotonin may be responsible 
for L-DOPA-induced hypothermia. 
E. Statement of the Problem 
Several studies have indicated possible alterations in 
the levels and metabolism of brain monoamines in SHR (Yamori 
et al., 1970; Nakamura et al., 1971; Shimamoto and Nagaoka, 
1972; Sjoerdsma, 1972; Goldberg et al., 197.5; Rosecrans and 
Adams, 1976; Versteeg et al., 1976, 1978). Several of these 
have been neuropharmacological in nature (Shimamoto and 
Nagaoka, 1972; Rosecrans and Adams, 1976) and only one has 
attempted to examine a central neurotransmitter system in any 
detail. This study (Rosecrans and Adams, 1976) attempted to 
correlate alterations in behavior of SHR to alterations in 
serotonergic mechanisms. This study found an increased turn-
over of serotonin and a decreased ability to habituate to 
stimuli which was suggested to represent a hyperfunctional 
serotonergic system in SHR. Neither of the catecholaminergic 
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systems have been studied in any detail. However, several 
studies utilizing L-DOPA have indicated changes in catechol-
amine metabolism in SHR (Shimamoto and Nagaoka, 1972; Tanaka 
et al., 1972). These L-DOPA-induced changes rely largely on 
presynaptic events as tpe L-DOPA must be converted to DA 
and/or NE, or release of serotonin before it can exert its 
effect. Changes in presynaptic levels and metabolism of the 
catecholamines could lead to alterations in postsynaptic 
events such as changes in sensitivity of postsynaptic receptors. 
There are extremely few studies which have examined post-
synaptic receptors in SHR by using direct acting catechol-
amine receptor agonists. One study used the direct acting 
DA agonist, apomorphine, to compare drug-induced behavior 
between SHR and Wistar rat (Shimamoto and Nagaoka, 1972). 
This study found no difference in response between the two 
rat strains indicating no change in receptor sensitivity of 
striatal DA receptors. However, receptor sensitivity of two 
other central dopaminergic systems remain unstudied. There-
fore there seems to be little information on DA receptor 
sensitivity in SHR. 
Since body temperature and Sidman avoidance responses 
to L-DOPA were reported to differ significantly from normo-
tensive controls (Shimamoto and Nagaoka, 1972; Tanaka et al., 
1972), suggesting possible alterations in dopaminergic 
metabolism and/or DA receptor sensitivity, the present study 
was undertaken to examine central DA receptor sensitivity of 
SHR. Apomorphine was selected as the dopaminergic agonist as 
it is postulated to be a direct acting agonist, and it is 
. f 
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capable of inducing three responses: 1) stereotyped behavior; 
.f.) locomotor activity; and J.) hypothermia. As stereotyped 
behavior is mediated via the neostriatum and mesolimbic 
forebrain, locomotion via the mesolimbic forebrain, and 
hypothermia via the hypothalamus, determination of possible 
alterations in central DA receptor sensitivity in SHR will be 
attempted by comparing the three apomorphine-induced responses 
obtained from SHR to those obtained from normotensive rats. 
MATERIALS AND METHODS 
A. Animals and Blood Pressure Measurement 
Three rat strains were utilized in this study: 1) the 
spontaneously hypertensive rat (SHR); Z) the Wistar~Kyoto 
rat (WKY); and l) the Wistar rat (NWR). The SHR and WKY 
were obtained from the breeding colony at the University of 
the Pacific School of Pharmacy. Both the SHR and WKY colonies 
were descendants of the original colonies in Japan. The 
breeding stock was obtained from Dr. J.V. Levy of the Pacific 
Medical Center, San Francisco, Calif. SHR has been maintained 
by brother-sister matings of animals selected for their high 
systolic blood pressure (greater than 180 mmHg). WKY has been 
maintained by randomized matings of animals selected for their 
normal blood pressure (a systolic blood pressure no higher 
than 145 mmHg). NWR were obtained from Simonsen Laboratories, 
Gilroy, Calif. Upon arrival, these rats were housed in 
groups of not more than 20 per cage in an animal room which 
was not under a 12 hour light-dark cycle but which was main-
tained at 22 26 °C until they reached proper age and weight 
(longer than one week). At this time their blood pressures 
were measured. SHR and WKY were housed in the same animal 
room which was maintained at 22-26 °C under a 12 hour light-
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dark cycle until their blood pressures were measured. Each 
strain was given food (Simonsen Laboratories Custom Lab 
Diet) and water ad libitum up until the time of the experi-
ments. All animals used were drug-naive males ranging from 
12 to 15 weeks of age. ·At this age the weights of the animals 
ranged from 250 to J50 grams. Animals were selected before 
the experiments were performed on the basis of their systolic 
blood pressures. 
Systolic blood pressures were determined in unanesthe-
tized rats by the previously described plethysmographic tail-
cuff method (Williams et al., 1939; Del Greco et al., 1953; 
Bunag, 1973). Before measuring, the rats were pre-warmed in 
a metal cage floated in a hot water bath (Precision Scienti-
fic, Company) for 10 min at 37 °C for the purpose of in-
creasing blood flow in the tail (Rand et al. , 196 5) • After 
warming, the animals were placed in a rat holder connected 
to a temperature control unit (Narco Biosystems) which was 
set at "8". A pressure cuff (E & lVI Instrument Company) was 
placed on the base of the tail behind which a bulb for the 
pneumatic pulse transducer (E & lVI Instrument Company) was 
placed. The bulb was held in place by the barrel of a 5 cc 
syringe which had been cut down to the same length as the 
bulb. The pneumatic pulse transducer was connected to an 
electrosphygmograph (E & lVI Instrument Company) which was in 
turn connected to the pressure cuff and a desk model physic-
graph (E & lVI Instrument Company; type DlVIP-4A). The cuff was 
inflated by a blood pressure cuff pump (E & lVI Instrument 
Company) which also automatically deflated the cuff. Upon 
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release of the pressure, blood flowed back into the tail. 
This blood flow set up pulsations which could be picked up 
by the pneumatic bulb which transmitted it to,the pneumatic 
pulse transducer. The signals from the pneumatic pulse trans-
-ducer were amplified by an amplification unit (Narco Bio-
systems) in the physiograph. The unit was calibrated before 
each session of blood pressure recordings by setting the 
deflection of the tracing stylus to 2.5 em on the graph paper 
(Narco Biosystems) for every 100 mmHg pressure. The 100 mmHg 
pressure was provided by pressing the "Calibrate" button on 
the electrosphygmograph. A minimum of three pressure mea-
surements were taken on each rat. After their blood pres-
sures were measured, the animals were divided into groups of 
three and maintained on a light-dark cycle of 800 to 2000 hr 
light for approximately one week before being used for an 
experiment. 
B. Stereotyped Behavior 
Animals were placed individually into clear plastic 
cages (Maryland Plastics; 44 em x 23 em x 20 em) and allowed 
to acclimate one hour before injection. The bottoms of the 
cages were filled approximately 1-1/2 em deep with bedding 
material (KC Pharmacal) upon which the animals could gnaw or 
bite. Screens constructed of cardboard were placed between 
each of the cages to avoid the possibility of the animals 
influencing each others behavior. 
Animals were injected with apomorphine at 5 min intervals 
with the first injection being made at 1300 hr. The apomor-
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phine-induced stereotyped behavior was then assessed by scor-
ing every 5 min according to the rating scale shown in Table 
I. Scores were then cumulated into 15 min-intervals for each 
rat for statistical analysis. All observations and scoring 
were made by several experienced observers who were not blind 
to the treatment. They assessed stereotyped behavior at two 
doses of apomorphine. The susceptibility of the rat strains 
to antagonism of apomorphine-induced stereotyped behavior was 
also assessed after pretreatment with haloperidol. 
E. Locomotor Activity 
After the animals had been on the light-dark cycle of 
800 to 2000 hr for one week, they were weighed in the morn-
ing and placed in a clear plastic cage of the same make as 
those used for the stereotyped behavior experiments. Unlike 
the stereotyped behavior experiments, these experiments were 
run with three animals per group in order to allow for normal 
social interactions. During these experiments the animals 
were allowed access to food (which was placed within the cage), 
but were not allowed water as drinking interfered with the 
activity counts recorded by the activity meter. At 1600 hr 
of the first day each of the animals was injected with 
1 ml/kg of vehicle. At this time, the water bottle was re-
moved from the cage. The spontaneous activity of the animals 
was measured overnight with the lights going off at 2000 hr 
and on at 800 hr. Each animal was again weighed on the 
morning of the second day. Water was given to the animals 
ad libitum at thi~ time. At 1600 hr of the second day the 
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TABLE I 
Stereotyped Behavior Rating Scale 
Assigned Scorea 
0 
1 
2 
J 
4 
5 
Behavior Displayed: 
Behavior indistinguishable from 
that displayed by untreated ani-
mals. 
Periodic sniffing, and/or repeti-
tive head and limb movements. 
Continuous sniffing with explora-
tory activity; and repetitive 
head and limb movements. 
Occasional or periodic gnawing, 
biting, or licking, and explora-
tory activity with continuous 
sniffing. 
Persistent and intense gnawing, 
biting, or licking with locomo-
tion restricted to a small area. 
Compulsive gnawing, biting, or 
licking at one location. 
(This rating scale was modified from those of Ernst (1965, 
1967), and Costall and Naylor (1973)). 
-
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animals were injected with a 2.0 mg/kg dose of apomorphine, 
the water was removed, and the activity recorded for 2: 
hr. Recordings were begun each day immediately after the 
third rat had been injected. 
Activity was measured by a Model "S" Selective Activity 
Meter (Columbus Instruments Company) with its sensitivity 
set at "5.0". The meter was always within a quiet room, and 
was allowed a warm-up period of at least 1/2 hr before the 
beginning of an experiment. Cumulative activity counts were 
recorded automatically every six min by a PC-1 printing 
counter (Columbus Instruments Company). 
The activity counts from the first day (overnight loco-
motor activity) were divided into 2 hr-intervals for each 
group of three rats for the purpose of determining whether 
spontaneous locomotor activity differs between the three rat 
strains. To determine the effect that apomorphine had on 
locomotor activity, the activity counts'obtained for the 
first 1-1/2 hr from each group of three rats for each day 
were divided into 18 min-intervals. The activity counts 
obtained during each 18 min-interval of the first day (vehicle-
injected) were then subtracted from the activity counts ob...,~ _ 
tained from the corresponding 18 min-interval of the second 
day (apomorphine-injected). This difference was considered 
to be the locomotor activity induced by apomorphine. 
D. Body Temperature 
Animals were placed individually into metal cages 
()0.0 em x 2).5 em x 15.0 em) covered on the bottom with 
--- -----------------------------~~--------- ------
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bedding material. The animals were allowed to acclimate to 
the cages for 1 hr before beginning the experiment. Body 
temperature was determined rectally by use of a Model 43 TA 
telethermometer (Yellow Springs Instruments Company) with flex-
ible thermistor probe (number 402). The probe was inserted 
4 em into the rectum and the temperature was allowed to sta-
bilize before being recorded (at least 30 sec). Experiments 
were started at 1100 hr when body temperature was first mea-
sured and recorded for each rat. Temperatures were then taken 
every 15 min for the entire duration of the experiment. The 
rats remained untreated for the first 2 hr of the experiment 
thereby allowing their body temperatures to equilibrate. Apo-
morphine or L-DOPA was injected immediately after the 1300 hr 
body temperature measurement. This temperature was used as 
the baseline temperature. Carbidopa was administered as a 
pretreatment 1 hr prior to the injection of L-DOPA and was 
injected immediately after the 1200 hr temperature reading. 
Haloperidol, in the experiments in which blockade of apomor-
phine-induced hypothermia was attempted, was administered 
immediately after the 1230 hr temperature recording. Tempera-
tures were taken for another 2-1/2 hr after the injection of 
apomorphine or L-DOPA. Changes in body temperature were deter-
mined for each rat by subtracting the baseline temperature 
from the temperature obtained every 15 min after the administra-
tion of apomorphine or L-DOPA. 
E. Drugs 
Apomorphine (APO) (Merck, Sharp, and Dohme Research 
,, 
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Laboratories) was used and weighed out as the hydrochloride 
salt. This drug was dissolved in double~distilled water 
immediately prior to injection. Concentrations of 0.25 and 
0.35 mg/ml of APO were prepared by diluting a volume of 0.5 
m~ml concentration of APO with an equal volume of double~ 
distilled water, and by diluting 7.0 ml of the 0.5 mg/ml 
concentration with J.O ml of d9uble-distilled water, respec-
tively. APO was administered in a volume of 1 ml/kg. 
L-DOPA (ICN Pharmaceuticals; and Sigma Chemical Company) 
and carbidopa (Merck, Sharp, and Dohme Research Laboratories) 
were used in their base form, and were prepared by a modifi-
cation of a previously described method (Ahlenius and Engels, 
1971). The 50 mg/kg and 100 mg/kg doses of L-DOPA, and carbi-
dopa (50 mg/kg dose was used in all experiments) were prepared 
in the following manner& 1) 75 mg or 150 mg of L-DOPA, or 
75 mg of carbidopa was dissolved in 0.4 ml of approximately 
2N HCl; 2) 2.2 ml of a propylene glycol solution was added to 
this acidic solution; J) this solution was in turn neutralized 
by 0.4 ml of approximately 2N NaOH. A 25 mg/kg dose of L-DOPA 
was prepared by: 1) dissolving 37.5 mg of L-DOPA in 0.2 ml 
of approximately 2N HCl; £) to which was added 2.6 ml of the 
propylene glycol solution; and 1) this solution was in turn 
neutralized with 0.2 ml of approximately 2N NaOH. These drug 
preparations totaled J.O ml and were injected immediately 
after their preparation as the L-DOPA or carbidopa would begin 
to precipitate. The particles that did precipitate out were 
held in suspension by the propylene glycol. Both the L-DOPA 
and carbidopa were injected in a volume of 2 ml/kg. 
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The propylene glycol solution was prepared by diluting 
J.O ml of propylene glycol (U.S.P., Fisher Scientific Com-
pany) with 7.0 ml of double-distilled water. 2N HCl was 
prepared by diluting concentrated hydrochloric acid (Mallin-
ckrodt) while the 2N NaOH was prepared by dissolving the pro-
per amount of sodium hydroxide pellets (J.T. Baker Chemical 
Company) in double-distilled water. 
Haloperidol (HAL) was obtained in pre-prepared ampuls 
of 5 mg/ml in a volume of 1 ml-CHardol_R_o-y-rv1cN1ri_l_)-.-N-i;"n"'e.-:--~---
tenths ml of the pre-prepared haloperidol solution was di-
luted with double-distilled water to a total of 15 ml to ob-
tain a concentration of O.J mg/ml haloperidol. A concentra-
tion of 0.5 mg/ml haloperidol was prepared by diluting 0.9 ml 
of the pre-prepared haloperidol solution with double-distilled 
water to a total of 9.0 ml. These solutions were kept refrig-
erated after being placed in vials wrapped with aluminum 
foil. HAL was administered in a volume of 1 ml/kg. 
A lithium chloride solution was prepared from lithium 
carbonate (J.T. Baker Chemical Company, Reagent Grade) by 
dissolving 7.389 gm to neutrality with concentrated hydro-
chloric acid. This solution was brought to 100 ml with double-
distilled water. The resulting concentration of lithium was 
2 mEq/ml. A sodium chloride solution was prepared by dis-
solving 11.700 gm of sodium chloride (J.T. Baker Chemical Com-
pany, Reagent Grade) in 100 ml of double-distilled water. The 
resulting concentration of sodium was 2 mEq/ml. These solu-
tions were used for chronic treatment of the three rat strains. 
The treatment schedule consisted of daily administration of 
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2 mEq/kg lithium or sodium at 1000 hr for 14 consecutive days 
(modified from Friedman and Gershon (197J)). On the 14th 
day a body temperature experiment using a 0.5 mg/kg dose of 
APO was performed on these chronically treated animals. 
A hydralazine HCl solution was prepared by diluting 5 
ampuls of 1 ml ampuls containing 20 mg hydralazine HCl (CIBA) 
to 1000 ml so that the resulting concentration of hydralazine 
HCl was 100 mg/1000 ml. This solution was given to a group 
o1· slili ad-r1oi-tl.II'!f1n place of-their drinKing water for 4 weeks. 
At the end of the 4 week period, a body temperature experi-
ment was performed on these SHR. The average volume of solu-
tion consumed by each rat during the course of the antihyper-
tensive therapy was determined to be 25 ml/24 hr. From this 
information it was calculated that each rat received approxi-
mately 2.5 mg hydralazine HCl for each 24 hr. 
All drugs were administered intraperitoneally (except for 
the hydralazine HCl) slightly to the right of the abdominal 
midline approximately half-way between the sheath and the 
sternum. One-milliliter tuberculin syringes equipped with 
25 G, 5/8-inch long needles (Becton-Dickinson) were used for 
all injections. 
F. Determination of Serum Lithium Levels 
A group of animals was selected for the purpose of deter-
mining serum lithium levels. These animals were chronically 
treated with lithium or sodium in the same manner as those 
animals used for the temperature experiments. At 1JOO hr of 
the 14th day these animals were decapitated and bled into open-
-~~----~--~---~-- ----------------------- -------------
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ed vacutainer tubes. The cells were allowed to coagulate and 
settle out. The sample was then centrifuged to obtain the 
serum to be analyzed for lithium. This analysis was performed 
by medical technologists at the Stockton Medical Pathology 
Group. As a result of sending the samples out, the analysis 
was performed by three different individuals on three separate 
occasions. These individuals were blind to the treatment 
schedule and therefore to whether the samples contained lithium 
or sodium. They analyzed the samples according to the follow-
ing procedure: 
A Varian Model 1000 atomic absorption spectrophotometer 
was used to analyze the serum for lithium. A light source of 
671 millimicrons was supplied by a Varian lithium hollow ca-
thode lamp with an operating current of 0.5 milliamps. The 
slit width was set at 0.5 nanometers. The burner was supplied 
with acetylene at 12 pounds per square inch with a flow of 3 
units on the instrument meter and air at 43 pounds per square 
inch with a flow of 5 units on the meter. The lithium stan-
dard (Instrumentation Laboratories) contained 1.0 mEq/1 ~ 
1.5 %. A stock solution of this standard was prepared by di-
luting 1:10 with a diluent containing 14.0 mEq/1 sodium and 
0.5 mEq/1 potassium. Two levels of control serum (by Hyland 
division of Travenol Laboratories) were reconstructed accord-
ing to the manufacturer's instructions and assayed with each 
group of unknown serum. Lithium control values were 0.5 + 
0.1 mEq/1 for level I and 1.5 ~ 0.1 mEq/1 for level II. The 
unknown and control sera were diluted volumetrically with di-
stilled water. Serum lithium concentration was determined by 
--------"7~-~~--=-~-~-~---~ ··-------
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the following procedure: 1) distilled water was aspirated 
first at a rate of approximately 4.5 ml/min and the percentage 
absorbance adjusted to 0.00 on the visual scale and 000 on 
the digital indicator; 2) the diluted standard was aspirated 
and the digital indicator set to 010 by the concentration , .... 
mode; .1) diluted controls and unknowns were then assayed and 
the initial concentrations of the unknowns were calculated by 
multiplying the number of units on the digital indicator by 
u--;-1-mEq/unrt-tHansen, i-9&5-)~.----------------------
G. Ambient Temperature 
All experiments were carried out at an ambient tempera-
ture of 23 + 1 °C. 
H. Statistics 
The data obtained for the following: 1) the cumulative 
stereotyped behavior scores for each 15 min-interval; £) the 
overnight spontaneous locomotor activity counts for each 2 
hr-interval; 1) the APO-induced locomotor activity counts 
for each 18 min-interval; and 4) the change in body tempera-
ture, were averaged and compared between SHR and the two 
normotensive rat strains by Student's t-test. Slopes of the 
log-dose response curves obtained during the body temperature 
experiments were compared by ANOVA linear regression. 
RESULTS 
A. Blood Pressures 
An e reva t-e-d-systo-1-1-c~b-l_o_o_d-pr-e-s-sure-tnat-wa:s-very-lTi-gh-Iy·----
significantly different from those of the normotensive strains 
existed in the SHR used for the present study. In this rat 
strain the blood pressure averaged 202 ~ 1 mrnHg (arithmetic 
mean~ standard error of the mean) (n = 157). Systolic 
blood pressures for the two normotensive rat strains averaged 
135 + 1 mmHg for WKY (n = 157), and 131 ~ 1 mmHg for NWR 
( n = 148). 
B. Stereotyped Behavior 
Two doses (O.j and 2.0 mg/kg) of APO were utilized for 
the assessment of drug-induced stereotyped behavior in these 
three rat strains. It was found that a 2.0 mg/kg dose of APO 
induced stereotyped behavior within a few minutes after injection 
and that at this dose the stereotypy lasted for approximately 
90 min. Gnawing behavior without motor activity, which is the 
most intense behavior, occurred mainly during the 15-30 min 
interval, although gnawing with motor activity occurred 
during the first 15 min after injection and also during the 
30-45 min interval. These results are illustrated in Figure 1. 
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This figure also shows, except for a single difference in 
significance during the 4th interval, that the six 15-min 
intervals of cumulated stereotyped behavior scores did not 
differ significantly over the 90 min. SHR, however, appeared 
to recover from the stereotypic effects of APO faster than 
either WKY or NWR. The smaller cumulated score during the 
45-60 min interval in SHR illustrates this possibility. 
Since the 2.0 mg/kg dose of APO may have been.a supra-
maximal dose required for the induction of gnawing, the 
stereotypic effects of APO at a second dose of 0.5 mg/kg 
were also assessed~ This dose also induced stereotyped 
behavior within minutes of administration, but the duration 
of stereotypy was only about half as long, 45 min, as with 
2.0 mg/kg APO. The intensity of the behavior observed at 
this lower dose was much less than that observed with the 
2.0 mg/kg dose. Occasional to continuous sniffing with 
exploratory type activity were the most intense behaviors 
induced by the 0.5 mg/kg dose of APO, and these behaviors 
occurred within the first 15 min as illustrated by Figure 
2. The 15-min intervals of cumulated stereotyped behavior 
scores again did not differ signifcantly between each of 
the three rat strains. It can also be seen that SHR again 
appeared to display a quicker recovery from these effects 
of APO than either WKY or NWR as no stereotyped behavior 
was observed in SHR during the J0-45 min interval. 
Total stereotyped behavior scoras covering the entire 
45 min for the 0.5 mg/kg dose if APO, and the entire 90 
min for the 2.0 mg/kg dose of APO show no significant dif-
-- ---------- ~~~~--
ference between the three rat strains as summarized in 
Table II. A significant difference may have been expected 
as suggested by the more rapid recovery from stereotypy 
by SHR. 
·To determine whether each of the rat strains was as 
susceptible to attenuation of the stereotyped behavior 
induced by APO as the other two strains, a O.J mg/kg dose 
of HAL was used to antagonize this stereotypy. As sho.wn in 
Figure J~1s dose of-HAL antagonized-t-n-e-st-erE:m-typ-e-d-be·-;;;;-;---~~-~­
havior induced by 2.0 mgjkg APO to approximately the same 
degree in each of the three rat strains. 
C. Locomotor Activity 
As rats are nocturnal animals, their spontaneous loco-
motor activity was assessed during the night while they 
were most active. Figure 4 graphically represents the over-
night locomotor activity counts obtained from each.of the 
three rat strains when their locomotor activity counts are 
divided into 2-hr intervals. No significant differences 
were found to exist between each of these three rat strains 
with respect to their overnight spontaneous locomotor 
activity. It can also be seen from Figure 4 that the loco-
motor activity increased significantly after the lights 
were turned off. As the locomotor activity counts did not 
differ significantly between the rat strains before the 
lights went off, the sudden increase in locomotor activity 
counts after the lights were turned off indicates that the 
one week light-dark schedule of 800-2000 hr was successful. 
---------------------------------- ---- ----.-.-=-=-=--"--··"c=.·.- --- ----- ---- ---------------- . 
Figure 1--Stereotyp~d behavior induced by 2.0 mg/kg 
APO. (For n values see Table II.) 
Key: CUM S B SCORES = Cumulated Stereotyped 
Behavior Scores; Time Interval 1 - 0-15 _____ _ 
minutes after injection with APO; 
2 = 15-JO min; J = J0-45 min; 4 = 45-60 
min; 5 = 60-75 min; 6 = 75-90 min. 
* = Significantly different from SHR 
CE.<0.05). 
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Figure 2--Stereotyped behavior induced by 0.5 rog/kg 
APO. (For n values see Table II.) 
Key: CUM S B SCORES = Cumulated Stereotyped 
Behavior Scores: Time Interval 1 = 0-1-~'-----------i----------------------------~m~i~n=u~t~e~s~a~f~t~e~r~injection-with APO; -
2 = 15-JO min; J = J0-45 min; 4 = 45-60 
min. 
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TABLE II 
Total Cumulated Stereotyped Behavior Scores 
Dose A:Q6morphine 0.,2 mgLkg ·- ~2-~om/Vkg 
Total Time ~2 min 20 min 
N b 2 NWR ().8 + 2.8 J9.b + 2.8 
- -Rat 
WKY 7.8 + 2.9 44.9 + 2.4 
- -Strain 
SHR J.J + 0.7 )).8 .:!:. 5.1 
-
Figure )--Antagonism of 2.0 mg/kg APO-induced stereo-
typed behavior by O.J mg/kg HAL. (SHR = 6 
rats; WKY = 8 rats; NWR = 6 rats.) 
Key: CUM S B SCORES = Cumulated Stereotyped 
Behavior Scores; Time Interval 1 = 0-15 
minutes after injection with APO (HAL 
pretreatment time= JO min); 2 = 15-JO 
min; J = J0-45 min; 4 = 45-60 min; 
5 = 60-75 min; 6 = 75-90 min. 
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The locomotor activity counts obtained after admini-
stration of APO were compared to the spontaneous locomotor 
activity counts obtained after administration of vehicle 
for each rat strain. Figure .5 shows the results obtained 
for SHR. In this figure it can be seen that the locomotor 
activity counts obtained after APO during the time interval 
of 36-.54 min was significantly greater than the spontaneous 
(vehicle-injected) locomotor activity counts of the same 
time interval. A significantly greater number of locomotor 
activity counts during the time intervals of 36-.54 min and 
.54-72 min was obtained after injection of.APO in WKY when 
compared to locomotor activity counts of vehicle-injected 
animals (Figure 6). Although not significantly greater, 
the locomotor activity counts obtained from APO-treated WKY 
were much greater during the 18-36 min interval than those 
obtained from vehicle-injected WKY. The locomotor activity 
counts obtained from APO-treated NWR were significantly 
greater than the counts obtained from vehicle-injected NWR 
during the time intervals of 18-36 min and 36-.54 min as 
shown in Figure 7. 
By subtracting the locomotor activity counts obtained 
after vehicle-injection from those obtained after APO-injec-
tion (Figures .5-7) one can construct Figure 8 which illus-
trates the actual degree of locomotor stimulation due to APO. 
This subtraction was done in order to determine the increase 
in locomotor activity induced by APO which, if APO truly 
induces locomotor activity, should be greater than normal, 
or spontaneous, locomotor activity. As can be seen from 
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Figure 8, APO-induced locomotor activity did not signifi-
cantly differ between the rat strains. However, the induced 
increase was much smaller in SHR than either WKY or NWR. 
Even though the increase in locomotor activity was much smaller 
in SHR than either WKY or NWR. Even though the increase was 
much smaller for each of the six 18-min intervals in SHR, the 
total increase in locomotor activity counts for the entire 
90 min was not significantly different between the three :, 
stra~ns as summarized-in Taol~III. 
D. Body Temperature 
Baseline rectal temperatures were not significantly 
different between SHR, which displayed an average core tem-
perature of )6.6 !_ 0.1 °C (n = 114), and NWR, which showed 
an average body temperature of ]6.7 + 0.1 °C (n = 118)., 
WKY displayed a baseline body temperature significantly lower 
than either SHR or NWR as its rectal temperature averaged 
36.2 !_ 0.1 °C (n = 139). 
The initial body temperature experiments performed 
utilized an intraperitoneal dose of 2.0 mg/kg APO. It was 
discovered that the hypothermia produced by this dose of APO, 
as shown in Figure 9, was of greater magnitude and more pro-
longed in SHR than in NWR. The decrease in body temperature 
was significantly greater in SHR during the entire duration 
of the hypothermic response when compared to NWR. WKY, on 
the other hand, displayed a hypothermic response similar in 
magnitude to that of SHR. Return to baseline temperature 
was faster, however, in WKY as there was a significant differ-
Figure 4--0vernight spontaneous locomotor activity. 
Experiment begun at 1600 hr. Lights off at 
2000 hr. 
(For n values see Figures 5, 6, and 7.) 
Key: Time Interval 1 = 0-2 hours after injec-
tion with vehicle; 2 = 2-4 hr; J = 4-6 
hr; 4 = 6-8 hr; 5 = 8-10 hr; 6 = 10~12 
hr; 7 = 12-14 hr. 
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Figure 5--Locomotor activity counts obtained after 
vehicle-injection compared to locomotor 
activity counts obtained after APO-injec-
tion: SHR (n = 11 groups of J rats). 
Key: 
* = 
Time Interval 1 = 0-18 minutes after in-jection with vehicle or APO; 2 = 18-)6 
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Figure 6--Locomotor activity counts obtained after 
vehicle-injection compared to locomotor 
activity counts obtained after APO-injec-
tion: WKY (n = 6 groups of J rats). 
Key: Time Interval 1 = 0-18 minutes after 
injection with vehicle or APO; 2 = 18-36 
min; J = J6-54 min; 4 -= 54-72 min; 
5 = 72-90 min. 
* = Significantly different from vehaicle-
injected animals (Q<0.05). 
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vehicle-injection compared to locomotor 
activity counts obtained after APO-injec-
tion: NWR (n ~ 8 groups of J rats). 
Key: Time Interval 1 = 0-18 minutes after in-· 
jection with vehicle or APO; 2 = 18-36 
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* = Significantly different from vehicle-
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TABLE III 
Total activity induced by 2.0 mg/kg APO for 90 Min 
Rat Strain ~nl Total Counts 
NWR ( 8) 1090.9 .:!:. .351. 0 
WKY (6) 1194.7.:!:. 516.8 
SHR (11) 4,35.0 .:!:. 292.4 
·········~····'·"··~---
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ence in the change in body temperature from 75 min to the end 
of the hypothermic response when compared to SHR. 
To determine whether this hypothermic effect was depen-
dent on the stimulation of DA receptors, HAL at an intra-
peritoneal dose of O.J mg/kg was administered 30 min prior to 
the APO challenge. As illustrated in Figures 10 and 11, this 
dose of HAL significantly attenuated the hypothermic response 
in NWR and WKY. This same dose of HAL also significantly 
antagonized the hypothermia in SHR as illustrated in Figure 
12. However, the drop in body temperature produced in SHR 
was still significantly greater than that produced in either 
NWR or WKY (Figure 1)). A dose of 0.5 mg/kg HAL was required 
in SHR to attain the same degree of attenuation provided by 
0.3 mg/kg HAL in NWR and WKY (Figures 12 and 1)). 
Graphic representations similar to the one obtained from 
the hypothermic response to 2.0 mg/kg APO were also obtained 
from the hypothermic responses to 0.25 mg/kg, 0.35 mg/kg, and 
0.50 mg/kg doses of APO. These curves are shown in Figures 
14, 15, and 16, respectively. At each of these three doses 
the magnitude and the duration of the hypothermic effect was 
greater in SHR than NWR. Only at the 0.5 mg/kg dose of APO 
was the hypothermic response more prolonged in SHR than WKY. 
Since these time-course curves of APO-induced hypotpermia 
employed log-doses of APO, construction of log-dose response 
curves from the results of these three doses was possible. 
These log-dose response curves were constructed by plotting 
the averages of the maximum decreases in body temperature 
displayed by each rat. Figure 17 shows the log-dose response 
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curves obtained for each rat strain. By use of linear re-
gression analysis it was determined that the slopes of the 
curves equalled: 1) 2.54 for SHR; g) 2.22 for WKY; and 1) 1.70 
for NWR. These slopes were not significantly different as 
determined by linear regression analysis. Since the magni-
tude of the decrease in body temperature was significantly 
greater in SHR in comparison to NWR for each of the three 
doses of APO, it was calculated that APO appears to be approxi-
mately 1.78 times (95% confidence limits: 1.37 to 2.JO) more 
potent in SHR than NWR. Or, in other words, that SHR appears 
to be approximately 1.78 times more sensitive to the hypother-
mic effect of APO than NWR. Because all three of the average 
maximum drops in body temperature for WKY did not differ sig-
nificantly from either SHR or NWR, apparent potency of APO in 
this strain was not calculated in comparison to either NWR or 
SHR. 
During these studies, it became apparent that different 
doses of APO were required to elicit the same time-course of 
hypothermia in the three rat strains. Figure 18 shows that 
a dose of 4.0 mg/kg was necessary to elicit the same hypother-
mic response in NWR as 2.0 mg/kg APO in WKY, and 0.5 mg/kg in 
SHR. These doses also appear to be threshold doses as 4.0 
mg/kg caused the same drop in body temperature as 2.0 mg/kg 
in WKY (Figure 19), and 0.5 mg/kg APO induced the same decrease 
as 2.0 mg/kg APO in SHR (Figure 20). Whereas the higher dose 
was capable of prolonging the duration of the hypothermic 
response in SHR, the hypothermic response to 4.0 mg/kg in 
WKY was not significantly different from that elicited by a 
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2.0 mg/kg APO. 
To ensure that this difference in temperature response 
was not a phenomenon specific to APO, a second dopaminergic 
agonist, L-DOPA (coupled with pretreatment of the DOPA 
decarboxylase inhibitor, carbidopa) was used. It was assumed 
that L-DOPA is metabolized to the neurotransmitter DA in 
the brain. Figures 21 to 23 illustrate the time-course of 
the hypothermic response to three log-doses of L-DOPA. 
These curves are strikingly similar to those obtained after 
administration of APO in that the duration of the hypothermic 
effect was greater in SHR than NWR. In contrast to APO, the 
hypothermic response was more prolonged in SHR than WKY at 
25 mg/kg and 50 mg/kg L-DOPA. A significantly greater 
decrease in body temperature occurred at 25 mg/kg and 50 mg/kg 
doses of L-DOPA in SHR than in WKY or NWR. At a dose of 100 
mg/kg L-DOPA the drop in body temperature was significantly 
greater in SHR than NWR. WKY at this dose of L-DOPA dis-
played a response somewhat intermediate to the other two 
rat strains and thereby did not differ significantly from SHR. 
Since log-doses of L-DOPA were used, it was again possible 
to construct log-dose response curves of the average maximum 
drop in body temperature per rat. The L-DOPA log-dose re-
sponse curves, as shown in Figure 24, are very similar to 
those obtained from APO. Slopes calculated for these curves 
equalled: 1) 1.83 for SHR; ~) 2.18 for WKY; and 1) 1.99 for 
NWR. These slopes were not significantly different from one 
another. The average maximum decreases in body temperature 
induced by L-DOPA were significantly greater in SHR than in 
.. ----·--
NWR at the high and low dose. Since the points at the ends 
of the curves differed significantly, the potency of L-DOPA 
in SHR in comparison to NWR was calculated. L-DOPA was found 
to be approximately 1.78 times (95% confidence limits, 1.J4 
to 2.35) more potent in producing hypothermia in SHR than 
NWR. Or, in other words, SHR appear to be approximately 
1.78 times more.sensitive than NWR to the hypothermic effect 
of L-DOPA. As with the APO data, potency of L-DOPA in WKY 
in comparison to SHR or NWR were not calculated as the 
hypothermic responses were not significantly different 
from either SHR or NWR. 
Chronic lithium treatment did not significantly affect 
the hypothermia caused by 0.5 mg/kg APO in either NWR or 
WKY as illustrated in Figures 25 and 26, respectively. Both 
lithium- or sodium-treated NWR and WKY displayed a maximum 
drop in body temperature of approximately 0.7 to 0.8 °C at 
JO min. Sodium-treated SHR, on the other hand, displayed 
a maximum drop of about 1.3 °C at J0-45 min as illustrated 
by Figure 27. This figure also shows that lithium treatment 
significantly attenuated the APO-induced hypothermic 
response in SHR. Instead of displaying a body temperature 
drop of 1.3 °C as in sodium-treated SHR, the lithium-treated 
animals displayed a drop of 0.7 °C at JO min in much the 
same manner as sodium- or lithium-treated NWR and WKY. There-
fore, as Figure 28 shows, lithium altered the hypothermic 
response in SHR so that it was similar to those displayed 
by NWR and WKY. Lithium-treated NWR differed significantly 
from lithium-treated SHR from 75-150 min. However, this 
difference occurred after the hypothermic response had 
ended. 
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The effect that lithium may have had on body temperature 
was roughly analyzed to ensure that it did not affect the 
response to APO by altering baseline body temperature, par-
ticularly in SHR. It was found that the baseline body tem-
peratures of sodium-treated rats averaged: 1) )6.5 ~ 0.1 °C 
for SHR; £) )6.7 ~ 0.2 °C for WKY; and 2) )6.4 ~ 0.1 °C for 
NWR~L1thium-treated rats demonstrated a lower baseTine 
rectal temperature which was )6.1 ~ 0.2 °C for all three of 
the rat strains. 
Serum lithium levels were 0.0 mEq/1 in sodium-treated 
rats, whereas in lithium-treated rats they were found to be: 
1) 1. 0 5 + 0. 11 mEq/1 in SHR; 2) 1. 24 ~ 0. 08 mEq/1 in WKY; and 
2) 1.01 + 0.05 mEq/1 in NWR. Blood pressures were measured 
on the 15th day (the day following cessation of chronic treat-
ment) and were found not to be significantly changed in either 
NWR or SHR (Table IV). However, the blood pressures in SHR 
were lower, though not significantly, after lithium treat-
ment. WKY blood pressures were not measured because of the 
lack of .a significant change in the other normotensive strain. 
Chronic treatment of SHR with hydralazine was found to 
normalize their blood pressure. The systolic blood pressure 
of these animals averaged 1)7 + J mmHg. Despite this nor-
malization of blood pressure, the hypothermia induced by 0.5 
mg/kg APO was not significantly different from the hypothermic 
response induced in untreated SHR (Figure 29). 
Figure 9--Hypothermia induced by 2.0 mg/kg APO. 
(SHR = 15 rats; v~Y = 25 rats; NWR = 24 
rats.) 
* = Significantly different from SHR 
(J2.<0.05). 
** ~ Highly significantly different from 
SHR ( £<0 • 01 ) . 
*** = Very highly significantly different 
from (J2<0.001). 
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Figure 10--Antagonism of 2.0 mg/kg APO-induced hypo-
thermia (n = 24 by O.J mg/kg HAL (n = 9) 
in NWR. 
Key1 TEMP - Temperature 
* = Significantly different from rats in-jected only with APO (£<0.0.5). 
*** = Very highly significantly different 
from rats injected only with APO 
(£<0.001). 
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F'igure :1.1--Antagonism of 2. 0 mg/kg APO-induced hypo-
thermia (n = 25) by O.J mg/kg HAL (n = .. 9) 
in WKY. 
Key: ~'ENIP = Temperature 
** = Highly significantly different from 
rats injected only with APO (:p_<0.01). 
*** = Very highly significantly different 
from rats injected only with APO 
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Figure 12--An.tagonism of 2.0 mg/kg APO-induced hypo-
thermia (n = 15) by 0.3 mg/kg (n = 9) and 
0.5 mg/kg (n = 9) HAL in SHR. 
Key: TEMP = Temperature 
* = Significantly different from rats 
injected only with APO (:Q.<0.05). 
** = Highly significantly different from 
rats injected only with .Are (J?.<O. 01). 
*** = Very highly significantly different 
from rats injected only with APO 
(J?_<0.001). 
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Figure 13--Change in body temperature induced by 
2.0 mg/kg APO after pretreatment with 
0. J mg/kg HAL in SHR , WKY, and NWR , and 
after pretreatment with 0.5 rngLkg HAL in 
:------------------------~S~H~R-.~(For n values see Figures 1~0~,~1~1~,~a-n~d----------
12.) 
Key: TEMP = Temperature 
** = Highly significantly different from SHR 
treated with O.J mg/kg HAL + 2~0 mg/kg 
APO (£<0.01). 
*** - Very highly significantly different 
from SHR treated with O.J mg/kg HAL + 
2. 0 mg/kg APO (:Q<O. 001 ) .• 
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Figure 14--Hypothermia induced by 0.25 mg/kg APO. 
(SHR = 13 rats; WKY = 8 rats; NWR = 9 
rats.) 
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Figure 15--Hypothermia induced by 0.35 mg/kg APO. 
(SHR = 8 rats; WKY = 9 rats; NWR = 8 
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Figure 16--Hypothermia induced by 0.5 mg/kg APO. 
(n = 9 for each rat strain.) 
Key: TEMP = Temperature 
* = Significantly different from SHR 
(Q<0.05). 
** = Highly significantly different from 
SHR (J2<0. 01). 
*** = Very highly significantly different 
from SHR (J2<0.001). 
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Figure 1.7--Log-dose response curves of maximum 
decreases in body temperature produced 
by APO. (For n values see Figures 14, 
15, and 16.) 
Key: MAX DROP IN B. T. = Maximum Drop in 
Body Temperature 
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*** = Very highly significantly different 
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Figure 18--Doses of APO required to elicit the same 
hypothermic response: 
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Figure 19--Hypothermia produced by threshold and 
suprathreshold doses of APO in v~Y. 
Key: 2.0 APO = 2.0 mg/~g dose of APO (n = 25 ~------------------------~--r-a~t--s ; 4.0 APO - .o mg/kg dose of APO 
(n = 6 rats); TEMP= Temperature. 
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Figure 20--Hypothermia produced by threshold and 
suprathreshold doses of APO in SHR. 
11 
c; 
O. APO = 0.5 mglkg,~d~o~s~e~of~A~P~O~--------------~ 1----------------------=~---T-( n=.__..;'_=-"=:9:-=_r_a-,-t=-s ~) ; 2 :·o APO = 2. o mg/kg 
dose of APO (n = 15 rats); TEMP= 
Temperature. 
* = Significantly different from 2.0 
mglkg APO (£<0.05). 
** = Highly significantly different 
from 2.0 mg/kg APO (£<0.01). 
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Figure 21--Hypotherrnia.induced by 50 mg/kg carbidopa + 
25 mg/kg L-DOPA. (SHR = 9 rats;;· WKY = 8 
rats; NWR = 7 rats.) 
Key: TEMP - Temperature. 
* = Significantly different from SHR 
(:Q<O.O)). 
** = Highly significantly different from 
SHR (P..<O. 01) • 
*** = Very highly significantly different 
from SHR (E<0.001). 
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Figure 22--Hypothermia induced by 50 mg/kg carbidopa + 
50 mg/kg L-DOPA. (SHR = 8 rats; WKY = 7 
rats; NWR = 9 rats.) 
- Temperature. 
* = Significantly different from SHR 
(:Q.< 0 • 0 5 ) . 
** ~ Highly significantly different from 
SHR (:Q<O. 01). 
*** = Very highly significantly different 
from SHR (£<0.001). 
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Figure 23--Hypothermia induced by 50 mg/kg carbidopa + 
100 mg/kg L-DOPA. (n = 8 rats for each rat 
strain.) 
Key: TEMP = Temperature. 
* = Significantly different from SHR 
(:Q<0.05). 
** = Highly significantly different from 
SHR (:Q<O. 01) • 
*** = Very highly significantly different 
from SHR (£<0.001). 
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Figure 24--Log-dose response curves to carbidopa + 
L-DOPA-induced hypothermia. {F'o·r n values 
see Figures 21, 22, and 2J.) 
Key: MAX DROP IN B. T. = Maximt~ Drop in 
Body Temperature. 
* = Significantly different from SHR 
(:Q<O. 05). 
*** = Very highly significantly different 
from SHR (:Q<0.001). 
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Figure 25--Hypothermia induced by 0.5 mg/kg APO after 
chronic treatment with sodium or lithium in 
NWR. 
Key: NA TX =Sodium-Treated (n = 8); 
LI TX =Lithium-Treated (n = 8); 
TEMP = Temperature. 
* = Significantly different from lithium-
treated rats (£<0.05). 
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Figure 26--Hypothermia induced by 0 . .5 mg/kg APO after 
chronic treatment with sodium or lithium in 
WKY. 
~----------------------~K~~~A-TX-=-~~d~um-Treat~d-\n-=-!~)n;----------------~ 
LI TX =Lithium-Treated (n = 10); 
TEMP = Temperature. 
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Figure 27--H~~othermia.induced by 0.5 mg/kg APO after 
chronic treatment with sodium or lithium in 
SHR. 
Key: NA TX = Sodium-Treated (n = 9); 
I,I TX = Lithium-Treated (n = 9); 
TEMP = Temperature. 
* = Significantly different from lithium-
treated rats (E<0.05). 
** = Highly significantly different from 
lithium-treated rats (£<0.01). 
*** = Very highly significantly different 
from lithium-treated rats (£<0.001). 
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Figure 28--Hypothermia induced by 0.5 mg/kg APO after 
chronic treatment with lithium. (For n 
values see Figures 25, 26, and 27.) 
Key: TEMP - Temperature. 
* = Significantly different from SHR 
(]2<0.05). 
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TABLE IV 
Blood Pressures Before and After Sodium 
~r~Li thrUITlT-rea tment 
Rat Treat- Blood Pressures 
Strain ment Before After 
{n} {mmHg} {mmHg} 
NWR Na. 134 + 2 144 + 6 ( 8) 
Li 134 ~ 3 135 ~ 4 
SHR Na 198 + 1 214 + 8 ( 9) -
Li 203 + 2 190 ~ 10 
-----------------------------------
Figure 29--Effect of chronic hydralazine treatment 
on hypothennia induced by 0.5 mg/kg APO 
in SHR. 
Key: :ttrn-~J\: == Hydralazine-,r-r-eated (n 8); 
NON TX = Non-Treated (n = 9); 
TEMP = Temperature. 
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DISCUSSION 
Results of the present study agree and disagree with 
several of those reported for earlier studies. The stereo-
typed behavior results, in particular, agree with those re-
ported by Shimamoto and Nagaoka (1972) thereby confirming the 
lack of difference in APO-induced stereotyped behavior between 
SHR and normotensive rat strains. SHR showed a spontaneous 
locomotor activity immediately after handling and placement 
into the test cage which was not significantly different from 
that of either WKY or NWR. These results conflict with the 
results obtained by other investigators (Shimamoto and Naga-
oka, 1972; Pappas et al., 1974; Rosecrans and Adams, 1976; 
Myers et al., 1977). However, the present study appears to 
be the first on the effect that a direct-acting DA agonist has 
on locomotor activity of SHR. Additionally, this is also the 
first study on the effect that APO has on the body temperature 
of SHR. These latter experiments have given further insight 
into the possible alterations of hypothalamic function of 
SHR. Therefore the objectives set down for this study have 
been met as to determining the possible alterations in DA re-
ceptor sensitivity in SHR in the: 1) corpus striatum; ~) meso-
limbic forebrain; and 1) hypothlalmus. 
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No significant difference in APO-induced stereotyped 
behavior was found to exist between the three rat strains 
either in onset, intensity, or duration. If SHR do possess 
supersensitive striatal DA receptors, then the gnawing 
behavior would have been more prolonged at 2.0 mg/kg APO 
than in the two normotensive rat strains. Furthermore, the 
intensity of behavior displayed at 0.5 mg/kg APO would 
probably have been greater in SHR. Instead, the duration of 
stereotyped behavior appeared to be slightly shorter in SHR 
which could possibly be suggestive of subsensitive striatal 
DA receptors. However, the intensity of stereotypy observed 
in each of the three strains was not significantly different 
from one another at either dose of APO. Therefore there 
appears to be no alteration in striatal DA receptor sensi-
tivity in SHR. 
The low intensity component of APO-induced stereotyped 
behavior is present upon return to normal behavior and this 
lower intensity of behavior is apparently mediated via the 
mesolimbic forebrain (Costall et al., 1975). This brain re~ 
gion is also apparently responsible for mediation of locomotor 
activity (Jackson et al., 1975; Costall and Naylor, 1976a). 
Serotonergic neuronal systems also apparently have an inhibi-
tory effect on these mesolimbic dopaminergic neurons which 
mediate iocomotor activity (Costall et al., 1976b) and may 
possibly have an inhibitory effect on the low intensity com-
ponent of APO-induced stereotyped behavior since it has 
locomotor activity incorporated into it. As APO has been 
suggested to activate central serotonin neurons and thereby 
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attenuate its own stimulatory effect on locomotor activity 
(Grabowska et al., 197.3a), it may be possible that the 
slightly faster return to normal behavior demonstrated by 
SHR is the result of stimulation by APO of the hypothesized 
(Rosecrans and Adams, 1976) hyperfunctional central seroto-
nergic neuronal systems present in SHR. 
APO was able to significantly increase locomotor activity 
in WKY and NWR for at least .36 min of the total 90 min, where-
as in SHR APO increased locomotor activity for only 18 min 
of the entire 90 min. In addition, APO-induced locomotor acti-
vity was much less, although not significantly, in SHR than 
either WKY or NWR. A possible explanation for such results 
is similar to the one suggested for the faster return to nor-
mal behavior from stereotyped behavior. Since central sero-
tonergic neuronal systems apparently inhibit the mesolimbic 
dopaminergic neuronal systems responsible for induction of 
locomotor activity (Costall et al., 1976b), and APO appears 
to stimulate these inhibitory neuronal systems (Grabowska et 
al., 197Ja), then the possible stimulation of the hypothesized 
(Rosecrans and Adams, 1976) hyperfunctional serotonergic sys-
tems in SHR may attenuate the locomotor stimulatory effects 
of APO. 
Both the stereotyped behavior and locomotor activity 
results obtained in the present study need further confirma-
tion. This could probably be best determined by direct appli-
cation of direct-acting dopaminergic agonists, including DA 
itself, to the corpus striatum and mesolimbic forebrain. 
This would, of course, require the implantation of bilateral 
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cannulae into the caudate nucleus and nucleus accumbens. 
Comparison of the responses elicited in SHR to those elicited 
in WKY and NWR, as in the present study, would supply fur-
ther information as to the sensitivity of the DA receptors 
in these areas of the brain in SHR. 
Spontaneous locomotor activity did not differ signifi-
cantly between the three rat strains. These results disagree 
with those of earlier studies which have indicated a greater 
spontaneous ocomotor activity in SHR (Snimamoto and Nagaoka, 
1972; Pappas et al., -1974; Myers et al., 1977), and a lesser 
spontaneous locomotor activity in SHR (Rosecrans and Adams, 
1976). These differences in results may be due to differences 
in experimental design. Whereas the present study was inter-
ested in locomotor activity, several of the earlier studies 
were interested in open field behavior as well as locomotor 
activity. Therefore in these earlier studies the animals had 
not been previously acclimated to their test cage or enclosure, 
whereas in the present study the animals had been acclimated 
to their test cage prior to commencement of the experiment. 
It may be possible that SHR will show greater exploratory 
activity and thus locomotor activity upon placement into 
strange surroundings than normotensive control animals. This 
increase in exploratory behavior and thus activity may be due 
to the animal's reaction to a new environment. Measuring an 
animal's reaction to new surroundings is the purpose of the 
open field test. Therefore these investigations may have mea-
sured "reactivity" whereas the present study, since the ani-
mals had already undergone their reaction to the environment, 
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In contrast, Rosecrans and Adams (1976) found activity 
to be less in SHR than normotensive rats upon placement into 
a strange environment. Upon repeated exposure to the test 
environment the activity of the normotensive control strain 
decreased dramatically while that of SHR changed very little. 
As a result, the locomotor activity of SHR subsequently became 
greater than that of the normotensive animals. This inves-
tigation apparently also measured reactivity rather than 
act1v1ty. It appears that the resu~ts ootained~n tne present 
study cannot be reconciled with those of the previously 
reported studies since the locomotor activity of SHR did 
not differ from either of the normotensive control rat strains 
utilized in this stud~. However, it seems that the earlier 
studies measured reactivity whereas the present study measured 
locomotor activity • 
. Furthermore, overnight spontaneous locomotor activity 
did not differ between SHR and the normotensive control strains. 
This would seem to provide further evidence that spontaneous 
activity does not differ between SHR and normotensive animals, 
especially when it is taken into consideration that rats are 
nocturnal creatures. In addition, if mesolimbic DA receptors 
of SHR were supersensitive or subsensitive, then compensatory 
mechanisms have occurred so that spontaneous locomotor activi-
ty remains similar to that of normotensive animals. Super-
sensitive mesolimbic DA receptors in SHR, however, are prob-
ably unlikely due to the smaller increase in locomotor acti-
vity induced by APO in SHR than WKY or NWR. The possibility 
of subsensitive mesolimbic DA receptors is at present diffi-
124". 
cult to eliminate and must await further investigations. 
APO elicited a significantly greater fall in body tem-
perature in SHR than NWR while the response elicited from 
WKY was intermediate to the other two rat strains at all doses 
used. As a result, the log-dose response curves obtained 
from the maximum drop in body temperature for the three rat 
strains were parallel to one another. Because of the signi-
ficant difference between SHR and NWR, it was determined that 
SHR than NWR. This apparent greater potency of APO could be 
due to one of several reasons. These reasons could also be 
used to explain why a larger dose of HAL was required in 
order to attenuate the hypothermic response in SHR to the 
same degree as in WKY and NWR. 
The first explanation is ·that SHR may metabolize APO at 
a slower rate than WKY or NWR which would thus allow APO to 
act for a longer period of time on the DA receptors. A slower 
rate of metabolic degradation of APO would not be inconsistent 
with the finding that ethanol is metabolized at a slower rate 
in naive SHR than naive NWR (Israel et al., 1977). It is 
known that approximately 80 percent of APO is conjugated with 
glucuronide in rat liver and then excreted in the urine (Kaul 
et al., 1961a, 1961b). The other 20 percent is apparently 
metabolized by both liver and brain catechol-0-methyl 
transferase (COMT) (McKenzie and White, 1973). Since the 
liver is the major site for the metabolic degradation of APO, 
alterations of liver metabolic enzymes in SHR could increase 
the sensitivity of this rat strain to APO. However, several 
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earlier studies have found that this is not the case. Pento-
barbital sleeping time was found to be significantly shorter 
in SHR than WKY which was suggested to be the result of a 
faster rate of metabolic degradation of pentobarbital in SHR 
(Willis and Queener, 1977). In a separate study it was found 
that the hexobarbital sleeping time, in vitro activities of 
microsomal enzymes, and the concentration of cytochrome P-450 
in SHR did not differ significantly from those of NWR (Vain-
tent with the concept of a slower rate of metabolic degrada-
tion of APO in SHR. In addition, if the rate of metabolic 
degradation of APO were slower in SHR, then the intensity and 
duration of APO-induced stereotyped behavior, and the duration 
of APO-induced locomotor activity should have been greater in 
SHR than in WKY and NWR rather than smaller as observed in 
the present study. It may be possible, however, that the 
greater amount of APO present due to its slower rate of break-
down and removal would allow stimulation of the hyperfunc-
tional serotonergic system in SHR (Rosecrans and Adams, 1976) 
thereby causing these APO-induced responses to inhibit and 
attenuate themselves. However, the alteration of the hypo-
thermic response in SHR by chronic lithium treatment would 
be difficult to account for by this hypothesis (as will be 
discussed later). 
It could also be suggested that there may be an altera-
tion in COMT activity in SHR which would have to be localized 
to the hypothalamus. However, it again would be difficult to 
explain the results obtained from the SHR chronically treated 
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with lithium (as will be discussed later). 
A second explanation for the observed difference in the 
hypothermic response is that there may be an enhanced 
distribution of APO to the brain of SHR. If this were the 
case, however, then APO-induced stereotyped behavior and 
locomotor activity would also have been significantly greater 
in SHR. This lack of difference is not surprising consid-
ering that APO is highly lipid-soluble and easily permeates 
r---~~~--r-~,h1 e--'ol-m::rd=hra±n=b-arrre-r~(-B -D-B)~.~T-rr-e-ref ore no sign:lfi-can t 
difference would be expected between the normotensive strains 
and SHR. This would be so even if there were a more permeable 
B-B-B present in SHR as suggested by Tanaka et al. ( 1972). 
As a result, any enhanced distribution of APO in SHR would 
have to be to the site of the hypothermic response which has 
been shown to reside within the preoptic anterior hypothala-
mus (Cox and Lee, 1977a, 1977b). 
APO has been shown to have a distribution to the hypo-
thalamus which is less than to the rest of the brain (Butter-
worth and Barbeau, 1974). An alteration within the brain of 
SHR which would allow a greater amount of APO to reach the 
hypothalamus could account for the increased sensitivity of 
this unique rat strain to the hypothermic effect of APO. This 
alteration would also have to alloW enhanced distribution to 
the hypothalamus of very lipid-insoluble compounds. SHR was 
found to be more sensitive than normotensive strains to the 
hypothermic effect of L-DOPA, a highly lipid-insoluble mole-
cule, in a manner similar to the way this strain was more sen-
sitive to APO. Additionally, chronic lithium treatment would 
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have to be able to correct this alteration as lithium treat-
ment changed the APO-induced hypothermic response to one 
similar to that shown by the normotensive strains. It seems, 
by this hypothesis, that lithium would also have to alter the 
distribution of' APO to various regions in order to correct the 
original dysfunction in distribution. Such an alteration in 
SHR which.can increase the distribution of both lipid-soluble 
and lipid-insoluble molecules to the hypothalamus, and which 
can be corrected by a positively-charged ion does not seem 
plausible. Therefore the possibility that a dysfunction exists 
within SHR brain that increases the distribution of APO to 
the hypothalamus can be eliminated. 
L-DOPA, as previously mentioned, was also found to 
cause hypothermia in much the same manner as APO. This seems 
to be clearly illustrated by the similarities in the log-dose 
response curv~s. Similarly to APO, L-DOPA also appeared to 
be approximately 1.78 times more potent in producing hypo-
thermia in SHR than NWR. These results would seem to suggest 
that the difference in the hypothermic response between SHR 
and NWR is not a phenomenon strictly reserved to APO. This 
would also argue against the first two explanations for the 
observed results; that is, that there may be an alteration 
of metabolic degradation of APO or that there may be an 
enhanced distribution of APO to the hypothalamus in SHR. 
On the other hand, these results would seem to indicate that 
in SHR there is some sort of postsynaptic alteration of the 
DA receptors responsible for mediating the hypothermic response. 
However, the mechanism of action of L-DOPA depends on pre-
128 
synaptic events as well as on postsynaptic events whereas 
the responses observed from APO, at the doses used, should 
have been the result of postsynaptic actions. Since the 
L-DOPA log-dose response curve of SHR was parallel to the 
log-dose response curve of NWR it may be assumed that the 
mechanism of hypothermia was identical in the two strains. 
Also, the APO log-dose response curves were parallel which 
would again suggest the same mechanism of action. Since the 
APO-induced hypothermic response depended on a postsynaptic 
site of action, it could be assumed that the presynaptic 
events in response to L-DOPA were the same in the two rat 
strains. Therefore it can be argued that the difference in 
the hypothermic response to L-DOPA between the two strains 
was also the result of postsynaptic alterations in SHR. 
It might also be argued that L-DOPA displaced serotonin 
from serotonergic neurons thereby leading to the hypothermic 
response (Maj and Pawlowski, 197.3; Reichenburg and Vetulani, 
197.3) and that APO indirectly stimulated the release of sero-
tonin from neurons which participate in the hypothermic re-
sponse (Grabowska, 1974; Przewlocki, 1976). As SHR have been 
hypothesized to possess hyperfunctional serotonergic systems 
(Rosecrans and Adams, 1976), stimulation of the serotonergic 
neurons involved in the mediation of hypothermia by either 
L-DOPA or APO may have led to the significantly greater fall 
in rectal temperature. However, the dose of L-DOPA used in 
the present study (25 mg/kg to 100 mg/kg) was smaller than 
those used in an earlier study (100 mg/kg and above (Maj and 
Pawlowski, 197.3)). Another study used intraventricularly-
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administered L-DOPA (Reichenburg and Vetulani, 197J). Both 
of these studies reported that the DA antagonists, pimozide 
and spiroperidol, were unable to attenuate the L-DOPA-induced 
hypothermia. In contradiction to these earlier investigations, 
it was observed during the course of the present study that 
HAL could significantly attenuate L-DOPA-induced hypothermia 
in SHR and NWR (personal observation). It may be that large 
amounts of L-DOPA are able to displace serotonin from seroto-
nerg1c neurons. ing response may be able to mask 
the responses resulting from DA receptor stimulation. Responses 
from lower amounts of L-DOPA may be the result of the conver-
sion of L-DOPA to DA and the subsequent stimulation of DA re-
ceptors. HAL also significantly attenuated APO-induced hypo-
thermia. Therefore the data obtained from the present study 
appear to indicate that the stimulation of DA receptors was 
responsible for the hypothermic response to L~DOPA and APO. 
As a result, it seems that the L-DOPA- and APO-induced hypo-
thermia observed in the present study was not due, either 
directly or indirectly, to the release of serotonin. 
Additionally, the results obtained from lithium-treated 
animals would not support the hypothesis that a serotonergic 
mechansim is the major contribution to the greater fall in 
body temperature induced by APO in SHR. Lithium has been 
found to interact with some of the serotonergi,c neuronal 
systems. Thus lithium has been found to decrease the amount 
of serotonin synthesized from L~tryptophan (Collard and 
Roberts, 1975). These results may be related to the observa-
tion that chronic lithium treatment can reduce brainstem sero-
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tonin levels by approximately 26 percent (Ho et al., 1970). 
This decrease in brainstem serotonin could also be used as 
an explanation for the attenuation by lithium of the APO-in-
duced hypothermia in SHR as it has been shown that it is 
brainstem serotonergic systems that participate in APO-induced 
hypothermia (Grabowska, 1974; Przewlocki, 1976). However, it 
seems reasonable that such a decrease in brainstem serotonin 
levels would also have occurred in the normotensive rat 
stra1ns. Therefore it seems plausible that chronic lithium 
treatment would also have attenuated APO-induced hypothermia 
in WKY and NWR. 
A third explanation is that in SHR there are postsynaptic 
alterations of the DA receptors in the hypothalamus which are 
responsible for mediating the drop in body temperature. This 
alteration in the hypothalamic DA receptor results in the 
greater sensitivity of SHR to the hypothermic effect of APO 
and L-DOPA. It was recently discovered that lithium has the 
ability to "stabilize" DA receptor sensitivity. This was 
accomplished by showing that concurrent lithium treatment 
could attenuate the increased response to APO-induced stereo-
typed behavior and locomotor activity observed when DA re-
ceptors are made supersensitive by chronic neuroleptic 
treatment (Gallager et al., 1978; Pert et al., 1978). "Sta-
bilize", as used by these authors, means that the lithium was 
able to return the sensitivity of the DA receptor to normal. 
Similar results were observed in the present study, except 
that the DA receptors are apparently already supersensitive 
in SHR. As a result, lithium was found to alter the APO-in-
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duced hypothermic response of SHR to that shown by WKY and 
NWR, just as lithium was able to alter the APO-induced be-
havioral responses of chronically neuroleptic-treated rats to 
that of untreated rats. Therefore it is suggested that the 
DA receptors of the hypothalamus responsible for mediating 
hypothermia are supersensitive in SHR. 
This supersensitivity may be due, according to Pert et 
al. (1978), toa 1) an increase in the number of DA receptors; 
~------~oT-£) an increase in the sensitiv1ty of the existing DA re-
ceptors. Pert and coworkers (1978) found that lithium could 
prevent the increase in DA receptor binding sites induced by 
haloperidol. These results support their suggestion that li-
thium prevents the development of supersensitive DA receptors 
by inhibiting the increase in the number of DA receptors. On 
the other hand, Stefanini and coworkers (1978) found that li-
thium could inhibit the stimulatory effects of DA on DA-sen-
sitive adenylate cyclase. They also found that lithium at 
brain concentrations above those required for therapeutic 
effect could inhibit basal activity of DA-sensitive adenylate 
cyclase. From these results it could be suggested that lithium 
prevents the development of supersensitive DA receptors by 
inhibiting the sensitivity of the existing DA receptors. 
Therefore, with the data available at the present time, it 
cannot be determined whether the proposed hypothalamic DA 
receptor supersensitivity in SHR is due to: 1) an increase in 
the number of DA receptors; or .f.) an increase in the sensitivity 
of existing DA receptors. 
Chronic hydralazine treatment was found to have no effect 
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· on APO-induced hypothermia in SHR despite being able to nor-
malize systolic blood pressure. These results would seem to 
eliminate any possibility that the difference in the hypo-
thermic response between SHR and NWR was the result of peri-
pheral vasodilating effects. That is, it would seem unlike-
ly that greater vasodilation in SHR, and therefore dissipa-
tion of heat from SHR, was the cause of the greater fall in 
rectal temperature produced by APO. This is because hydrala-
zine is a smooth muscle relaxant and had already dilated the 
vasculature of SHR as evidenced by the normal systolic blood 
pressure. As lithium was observed to slightly decrease blood 
pressure in SHR, it could have been suggested that the altera-
tion of the hypothermic response to APO in SHR by lithium was 
due to this decrease in blood pressure. Therefore, if the 
greater hypothermia induced by APO in SHR was the result of 
greater vasodilation, then hydralazine would have been able 
to alter the APO-induced hypothermia in the same manner as 
lithium was able to alter the hypothermic response. Since this 
response was not the same after chronic treatment with hydrala-
zine or lithium, and hydralazine exerts its effect on the peri-
phery, this suggests that lithium affected APO-induced hypo-
thermia via a central mechanism of action. Therefore it ap-
pears that the lack of significant effect on APO-induced hypo-
thermia in SHR by hydralazine supports the suggestion that 
the hypothalamic DA receptors responsible for mediating hypo-
thermia are supersensitive in SHR. 
The hypothermic responses obtained from WKY are more dif-
ficult to explain in that their responses were intermediate 
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to those of SHR and NWR. These results are similar to bio-
chemical studies in which significant differences between SHR 
and NWR a+e lost when SHR are compared to WKY (Sjoerdsma, 
1972; Yamabe et al., 197.3; Osumi et al., 1974). Such obser-
vations have led to the controversy as to whether WKY or NWR 
is the proper control strain for comparison to SHR. It has 
been suggested that WKY may possess hypertensive traits (Sjoerd-
sma, 1972), and therefore the similarity in response of WKY 
to SHR may not be critical. However, the hypothermic re-
sponse to APO of lithium-treated WKY was not significantly 
different from the hypothermic response produced by APO in 
sodium-treated animals. These results suggest that no differ-
ence exists between WKY and NWR as the APO-induced hypothermia 
was not affected by chronic lithium treatment in either rat 
strain, but that there is a difference between WKY and SHR as 
the hypothermic response elicited in SHR was altered by 
chronic lithium treatment. 
It appears that the most plausible explanation for the 
results of the present study is that the hypothalamic DA 
receptors responsible for mediating hypothermia are super-
sensitive in SHR. This proposed alteration in hypothalamic 
function is consistent with previous studies which have also 
reported alterations in various hypothalamic functions in SHR. 
Thus Bunag and coworkers (1975) hypothesized that the poster-
ior hypothalamic pressor areas of SHR are hypersensitive. 
These pressor areas have recently been related to hyperacti-
vity of the sympathetic nervous system (Juskevich et al., 
1978; Takeda and Bunag, 1978). Schmid et al. (1978) discovered 
that cAMP levels are lower in SHR than WKY which was sug-
gested by these authors to indicate a possible alteration of 
the adenylate cyclase-cAMP-phosphodiesterase system in hypo-
thalamic structures of SHR. By observing elevated basal pro-
lactin release and normal suppression of prolactin release 
in SHR, Sowers and coworkers (1979) hypothesized that hypo-
thalamic DA metabolism is defective in SHR. Thus the results 
of the present study appear to be in agreement with other 
studies that have postulated alterations of normal hypothala-
mic functions in SHR. 
The conclusions of the present study obviously requires 
further experimentation and verification. There are a number 
of procedures which might be employed in an effort to confirm 
this hypothesis of SHR hypothalamic DA receptor supersensi-
tivity. Regional activity of DA-dependent adenylate cyclase 
could give an indication as to the sensitivity of the hypo-
thalamic DA receptor in SHR. Additionally, regional DA re-
ceptor binding studies may also be helpful. Furthermore, it 
would be interesting to determine if there is a common denomi-
nator between the greater sensitivity of SHR to the hypother-
mic effect of APO and L-DOPA, and their greater sensitivity 
to the inhibitory effect of L-DOPA on sympathetic nerve acti-
vity (Judy et al., 1978). This may give a clue as to whether 
or not the postulated supersensitive DA receptors are related 
to the pathogenesis of hypertension in SHR. Studies such as 
these will be required to confirm the suggestion that the 
hypothalamic DA receptors responsible for mediating hypother-
mia are supersensitive in SHR. 
CONCLUSIONS 
1. There was no significant difference in stereotyped be-
havior induced by the direct-acting DA agonist APO be-
tween SHR and two normotensive control strains, WKY and 
NWR, suggesting that there is no alteration in the sen-
sitivity of DA receptors in the corpus striatum of SHR. 
2. There was no significant difference in locomotor acti-
vity, either spontaneous or induced by APO, between SHR, 
. WKY, and NWR, suggesting that there is no alteration in 
the sensitivity of DA receptors in the mesolimbic fore-
brain of SHR. 
Ja. SHR demonstrated a significantly pronounced and prolonged 
hypothermic response to APO and L-DOPA than NWR. 
b. WKY displayed a response intermediate to SHR and NWR; 
this may be due to the possession of hypertensive traits 
by WKY. 
c. Lithium significantly attenuated APO-induced hypothermia 
in SHR, and altered it to a response similar to WKY and 
NWR. 
d. Since lithium has the ability to "stabilize" supersensi-
tive DA receptors, and APO-induced hypothermia in SHR, 
it is suggested that DA receptors in the hypothalamus 
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responsible for mediating hypothermia are supersensi-
tive in SHR. This supersensitivity may be the result 
of: 1) an increase in the number of DA receptors; or 
2) an increase in the sensitivity of the existing DA 
receptors. 
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